2021-06-30-accounts

British Society for immunolog Annual Report 2021

| Trustees, Report For the year ended 30 June 2021 What we do and why ft matters The Brlt15h Soclety for Immunology Is the award wlnnlng (Best Overall Asso¢iation 2020, The Assoclatlon Awards) and leadlng UK membership or8anisation worklng with selenilsts and ¢linlclans from academia and industry to forward immunolo8y researth and application around the world. Our friendly. accessible community consists ol over 4,LKIO immunobogists. 8ivinB us a powerful volce to advocate on Immunologlcal sclence and health for the benefit of society. The Soclety support51ts member5, Students and the wider publlc to learn more about Immunolo8V through dlssemlnatlng researth and provldln8 re50UTces, actlvltles and grants to ald educatlon In th55 fleld. Immunologkal scSence underpln5 many a5perts of human and animal health and disease, from communiuble dlsease and vacclnation to the managernent and treatment of many chron1¢ ¢onditlons. ThTOU8h enhanclng our knowled8e of how the Immune system functlons for the publlc benefit, the Brltlsh So¢lety fcsr Immunology Can play a kty role in advancln8 Socletvs ablllty to prevent and treat di5ea5e. Our mlsslon The Brltish Soclety for ImmunokJ8Is mi551on15 to promote excellen¢e In immunolo8l¢al research, scholarshlp and cllnlcal practite in order to improve human and anlmal health. We accompllsh thls bv.. WorklnB wlth our members to support current and future 8eneratlons of Immunolo81sts, Sharing our passlon for Immuno108V through meetlngsi publlcatlons and the medla. Bulldln8 up an understandlng of our work by en8a8ln8 wlth the publlc and those worklnB In the research and health envlronments. Workln8 wlth partners In pursult of our rni551on, bulldlng on common Interesls The Trustees conflrm they have referred to the charlty Cornm1551on's 8uldance on publlc benefit when revlewln8 the Soclety's alms and objectlves, plannlng fvture actlvltSe5 and setting the annual operatSn8 plan.

Our strategic oblectlves l.. Gr¢Jw Ini)iiil)Lir¥hip 2. Pi'uii)otè I'lle iiitLAI-Ilil'iokiillsiTI C)f Iiiii'iiuii()Ii)LY -4. L)ovt)Ioii (111 11)tLll•yfiil.É>cl piil.lliLations %tl-dtpvy 4. 1'.:.xti!iid ihur i'(41(.IVclllC.P. (>l)il ii'fii)14(',i tlir(iiiiJki Oli￿ i)(-ilic.y iiiid L¥xl'L>rntil ¢iffair% <l¢tivitio.s S. Divpi'sify niir ini(JIIIL Meiiiborsl)ip Our rnembers are at the heart of everythin8 we do. The Unlted Kln8dom is a world leader in Immunologital research, and Immunolo8y underplns many aspects of recent advances In our knowledge ol human and anlmal health and dlsease. As the lar8est Professional immunology society in Europe and third lar8est in the world, we are a friendly, accessible community for irnmunolo8lSts Irom all disciplines, whlch supports dlverslty and works across dlfferent sectors and national borders. We work with members from across the spectrum ol the di5clpllne, from basic science through to clinlcal appllcatlon. and from diflerent sectors, to support current and future 8eneratlons of Immunologlsts. Membership of the Brltlsh Soclety for Immuno108y brln85 many benefbts. These Include d15count5 to our meetln85 and to our exceptlonal 8SI Congress, access to a dlver5e ran8e o18rants, bursarles and priies, free a¢¢ess to our lournais and much more. The Society provldes tallored support for OUT communlty throu8h our hlghly valued Reglonal and Affinity Groups, but we are also there to represent immuno108y to the wlder world. Members value our strong voice to Speak out with Influen¢e and Impact on behalf of Immunology In pollcy, public engagement and the Tnedia. At the end oflune 2021, we had over 4,000 members who join us from all walks of Immunology. From students up to senlor levels, they contribute to our work throu8h many different routes. Includrn8 speaking at our Conferences, helplng wlth our public engagement aCti￿tIeS and advlsln8 on our pollcy work- our grateful thanks 80 to our whole immunolo8y communlty.

.•coN'NE.CTING IIMMUNOLOGY BSI VIRTUAL CONFERENC,E ? ?O.' of inspirirKJ scientif ic Cci, tent i¢fiJ

8'.S"Iivlrt ts,ail Qabslcofft.'9.1'Q.S>

The BSI'S first ever vlrtual ¢onferen¢e.'Connectlng immunolo8y in the time of COVID-19', took place on 1-2 December 2020. We welcomed over 780 attendees and connected wlth people from 31 countrles. We were honoured to welcome Slr Patrtck Vallance, the UK Government's Chlef Scientlflc Advlsor, to joln the 'Immunoh)8v and COVID-19' plenary se55ion which a150 featured a presentation from Professor Paul Moss and Dr john Grain8er on behalf of the UK Coronavirus Immuno108y Consortium IUK.CICI. SpÈakin8 on the day that the Pfl2er-8ioNTech COVID-19 vacclne was approved for UK use, Sir Patrick refiected on hls role of Chlef Sclentlfic Advlsor durlng Ihe pandemlc and the huge advance5 that we have made In our understandlnB olthe dlsease's blolo8Y, treatfflents, and vacdnes. We hope to reunlte In person In November 2021 for the return of the BSI Congress in the beautlful clty of Edlnbur8h. Rollonal and Afflnlty Groups The BSI'S Regional and Afflnlty Groups are a key part ofthe BSI commvnlty and carry out much of the core actI￿ty of brlnglnB our membershlp tO8ether. The sclentlflt dlscu55bons and networkln8 that take place at these meetlngs are Invaluablè for the contlnued development of Immunolo8y. The stren8ths of our 17 Regional Group5 are to brlng together immunolo8ists wiihln a local communlty, boostlng local research networks. The 12 Affinlty Group5 have all been created to focus meetiAgs and discus51on5 on speclfic areas of immunology and they contlnue to evol¥e as Immunology expands Its reath and knowled8e. Our programme of events was dlsrupted by COVID-19. however, many of the BTOUPS swltched thelr events onllne and were able to keep membèrs engaged and up to date wlth almost 3.500 people attendln8. It Is plartned to reintroduce physlcal events when restrlctlons allow.

Keeplni members Infornied The BSI works har(1 to ensure 8ood communication channels wlth our members to keep them Informèd about our activities and about developments in immuno1ts8y in thè wider wodd. This has been a particularly important part of our activities this year with the COVID-19 pandemlc. The popularity of our website tontlnués to arow wlth over 4.22 million page views this year and 2.38 million unique user5. Thls is an Increase of 59% and 92% respeclively compared wlth last yeai's figures. The Biteslied Immunolo8y section contlnues to be popular along with our new Coronavlrus Information hub, which collects the B51.5 a¢tlvitles on COVID-19 wlth Useful resources for (trur members and the wlder public. Our Info8raphlc5 on COVID vacclnes are the most vlewed pages on the slte. 4.22m page view&, 2.38m nlque users B51 emall Comrnunlcatlons to members and addltlonal subscrlbers have become a malnstay for keeplng the Immunology communlty Informed and Connected, wlth audlence numbers 8rowln8 con51derably over the Course of the year. Our fla85hlp membershlp magailne ImmunohgyNews Is publlshed quarterly and contlnues to be a popular way of en8a8ln8 wlth our members, The magaiine includes feature artlcle5 from leadlng Smmunologlsts. an educatlon and ca￿eT$ sectlon and more informatlon on our activitles. A5 It contalns many artlcles likely lo be Of interest to a broad audlence range, It Ls an Important part of our WO￿ to increase exposure of the B51 to the Immunolo8y communlty and beyond. Our social medlb channels contlnue to grow In Importance as a way of en8agln8 With our membershlp and the wlder world at a more Immediate level, to Interact wlth our supporters and spread the word about our work and the wonders ol Immunology. Thls year has been a 5ucces5 Story for OUT sodal medla channels wlth touchpolnts such os BSI vlrtual conference, ourvacclni Engawnenl St¥rts ¥1 Home campal8n and our coronavlrus work belng espedally Influentlal In dTlvln8 our en8agement figures. We have also run several campal8n5 to hl8hll8ht the dlvwslty of our membershlp, Includin8 SUPPOrtln8 Women Ih Sclence Day and

81acklnlmmuno108y week. Twltter has seen an Sncrease in followers of 31% compared wlth last year, whlle

our Llnkedln audience has grown by 44%. We've also seen a significant Increase in our In5ta8ram followlng and en8a8ement, partlcularly amon8St non-immunolo8lst follower5 drlven by our Interaulve COVID-19 vacclnes Q&A5. OUT posts on Twhtter were seen almost 4 mlllion time5. A¢r055 all channels, our soclal medla posts were seen over 3.6 mllllon times, with Llnkedln at 580k and Facebook at almost 7CK)k. 31% 3.6 million More Twltter fol￿werS More ilnkedkn followevs I medla p05t

Supportlng mÈmbpr5 throu•￿￿t thelrcareer The 851 is a hub of expèrtiseto support our members In forgin8 stron8 careers in the many sectors in which immunolo8lSts are employed. It is essential that our members feel supported at all stages of thelr careers, from undergraduate throu8h tts retirement. and beyond. One of our core responslbllStles 15 to offer career5 and educational support to current and future Benerations of Immunolo815t5. We do this throtsgh ongolng initiatives. such as our 8rants schemes, Our education webslte Blteslzed Immunology and our highly rated mentorin8 scheme. Bltèslzèd ImmwioloK Bltesized Immunologyls our hl8hly popular onllne educatSonal resource which provides a comprehensive overvlew of the Immune system, delivered In short 5ell-contained articles that highlight major'take home, Messages. The content15 de518ned lor use by blosclence undergraduates, A-level students and anyone with an Interest In the subject. Thls year. we have ¢ontinued to review current contènt and comm1551on new artlcles to ensure we keep up to date with the immunoloBy fleld. Ea¢h month, 8lteSlzed Immunology re¢elves an average of 192,502 pa8e vlews, up 70% from last year. Teachln8 r•co8nltlon Supportln8 hS8her educatlon Immuno108V teachers 15 Important to ensure that the next 8eneratlon are Inspired to lollow a career In Immunology. The BSI runs several initiatlves to support this sector of membershlp. Our Imrnunolo8y Teachln8 E¥¢ellence Award recognlses outstandln8 immunology teachers al higher educatlon In5titute5 In the UK. Now in its fourth year, we were dellBhted io present Ihe award to Dr Nlgel Froncls, a Honorary Associate Prolessor at the Universlty of Swansea Medlcal School. Thejud8e5 felt that Nl8el was a dedicated and passlonatè immunolo8lst who demonstrated commltment, Innovation and ¢reatlvSty In hls teaching to bring the s¢Jblect to life to student5 at all levels. It was clear to the lud8e5 that Nlgel's teathlng sklll Is valued by S¢udent5 and colleagues allke. Mentorln8 5chem• The success of our mentorlng scheme ha5 Colltlnued apace. Thls key part of our strateglc plan alms to support professlonal development among the Immunolo8y community, bringing tO8ether senior scientlsts wlth earlv career researchers to asslst the next generation of immunolo815t5 wlth career development and pro8resslon. Our 2020 intake of 8 mentor-mentee pair$ all valued the Scheme and f6nlshed well wlth posltlve feedback all Tound. For 2021, the popularity ol the scheme more than quadrupled to 50 mentors and mentees takln8 part Iwhlch does indicate ihe need for thls type of actlvlty wlthln the communltyl. Due to the pandemlq tralnln was switched onllnè but thls has Inueased a¢¢essibillty of the scheme. Inltlal feedback Indlcates the scheme Is worklng well. WSnt•r Sth¢Jol An important part of our misslon 15 tv 5UPPOrt fvrture generations of Immunolo815ts. Thls year, we adapted our Wlnter School event to a virtual settlng. Thls one-day online event gave immunology students at a Masierfs deBree level the opportunity to hear from top Immunologist5. Wlth over 260 people reglsiered, the delegates heard from 6 leadSng Immunologists gSvin8 tallored talks on the latest updates In thelr area alon8 Wlth the opportunity to ask questlons. There was also a career development session and a mentsl wellbeing session. Feedback on the event was very posltsve.

C•r4er D•wloprn¢rf Weblnars Provlding access to tredlble, useful and informative careers resourtes is a key aim of the BSI. Thls year, we tontinued our success in prowding webinars on different aspects of career developmen( providing all members, no matter where they are based, with access to our cafeerfs resources. We completed our initial webinar series whlch took a wide-ran8ing look at the dlfferent types L)f skllls that BSI members need to be 5ucce55ful in thelr careers. ThSs Included how to mana8e a lab Successfully and how to wrile a 8rant appllcatlon. Thls was followed up wlth a slx-part weblnar serles for BS1 member5 oh'careers in immunology.. Thls looked at the different career routes that Indlvlduals Can take after Studying ImmunoloBy, ranglng from publishing, publlc engagement and lab technician. This has been a partlcularly important offerin8 to our early career members to allow them to find out more about the opportunities open to them. Feedback has been hu8elv posltlve. Grants to 5UPPOrt m•mb•rs A 518nlfkant proportbon of BSI funds15 dlstrlbuted to Its members through our 8rant schemes to support their resear¢h, help them to bulld thelr transfernble skills and io partlclpate In outreach prolerts. Although some of our grant scheme5 were dlsrupted by the COVID-19 pandemic meanin8 some actlvltles- su¢h a5 travel to Internatlonal conferences- could no lon8er 80 ahead, the BSI remaln5 committed to supportlng Its members through these schemes In the future when ¢lr¢umstances allow. Tr•vql Awards Ind Lab Plac•ment fjr•nts All travel award schemes were paused by the society In line wSth government 8uldance. We plan to re-open the awards when the sltuatlon allows and physlcal Conferences resume. Communlutlng Immunolo8y Gr•nts We supported 8 projects through thls 5theme wlth the alm of stlmulatln8 intere5L dlscusslon and understandln8 of Immunology among a public audlence. Prolects ranBed from creatin8 animated vlde05 to explaln how COVID-19 vacclne5 work to Illustratlons about how the Immune system fl8his ol patho8ens. Equallty, Dlverslty & Inckmlon Acilvlty Grants Thi5 hew grant scheme almed to support 851 members by funding actlvltles and events that promote dIvers￿y and Inclusion across the immuno108y communlty and the wlder blomedlcal sclences. In thls pllotyear of the Scheme, we lunded 7 grants. Proletts ranged from fundln8 a workshop to support researcher mentsl health to a project to decolonlse and dSveTsIfy some Immunolo￿ units on the unlverslty ¢uirlculum. Prt)miTrtlniJ tlip iiitprn<ilinniill<bln nf i1771111tr*olnr'i As Immunological research develops. the International networks that underpln our cuttln8-ed8e, cross- dlsclpllnary discoveries become increa51ngly Important. The Society ha5 always been ambitlous In terms of our international reach, something we know our members value highly. We understand that It's now more important than ever for us to have a promlnent voice on the international stage, speaklng up for immuno and the UK research communlty. We actlvely en8age with our Internatlonal Counterpart5 on a regular basis through membershlp of the European Federatlon of Immunological Societles IEFISI and the Intemational Union gf lrnmunolc8ical Socleties

European Federatlon ol Immunologlcal Sodètl•s IEFIS} The BSI 15 leading the EFIS taskforce on vaccines. The taskforce alms to work together to promote evidence- based information on vaccines across Eurtspe, lookin8 at how we can influence the policy environment. The taskforce will è150 be a forum to share information and promote best practlce beiween societies. The taskforce has mède good proBre5S this year, publishin8 a policy document in February on COVID.19 vaccSnes. Thls was used by EFIS members to send to the4r Bovernment5 to provlde evidenced-ba5ed informallon on COVID-19 vacclnes. Plans are now underway on the public engagement front too to provide translated Informatlon resources for the public on how vaccines work and commonly asked questlons around COVID-19 vac¢lnes. The BSI is takin8 part In an Inltiatlve entltled YEFIS lyoun8 EFISI to create o network of early career ￿searCherS across Europe. The group have several plan5 Includln8 h05tin8 5e5sions at the upcoming European Congress of Immunolo8V. In lune. the UK hosted the world's first Global Vacclne Conlidence Summit. Brln8ing together publlc and prlvate sector experts from afound the world. the summit almed to drove foTW3rd collectlve actlon to bulld global vacclne conlldence and Increase vacclne uptake In the fl8ht 38alnst COVlD-19. We ran a c3mpal8n calling on the UK Government to make improvln8 8lobal vacclne confldence a speclflc legacy project of the 2021 G7 conference. As well as ￿￿tIng to the Prime Minlster, our members alsoloined us on 50clal medla to ralse thelr volces and amplify thls message. riniJ¢blAY si.Il%!I￿ll iThfj. Er'4+oni' The BSI'S origlnal ethos stlll lies at the heart ol our So¢iety-to diiseminate research wlth the alm of promotlng and advancln8 immunoloBy to loster future Snnovation. The B51 Is proud to achieve thls alm through the publl¢atitsn of our two well e5tabllshed offlcial lournals, Immunology and Cllnlcol & Experlmenrol Immunolooy, Working wlth the publisher Wlley. ourjournals provide a s18nlflcant proportlon of the Socletls Income. IVS been a busy year for loumals as we work hard to ensure they malntaln thelr competltlve edge consldèrlng the current changes In the ptsbllshing Industry. 2020 saw the Impact factor for Immunology cllmb from S to 7, It5 hl8hest ever. Immun 7.397 859,600 downloads 696 submissbon<: Impart Fattor 12020.. 650.1571

Cllnical & Experlmental Immunology Thè Journal of Translatlonal Immunology immunolog ClinicGI& Experimentol Immunology had anothergood year wlth an Inuease In submlsslons and 43% more downloads. It reached its hl8hest Ifflpactfactor of 4.330 drlven by sU￿$Sfvl revlewserles. 4.330 969,360 downloads 12020: 680,1711 43Yo Impart Fattor More downlo Immunotherapy ADVANCES Our new open acces5journal, ImmunothempyAdvunces, was launched In November. The number of submlsslons has been encoura8ln8 hlttln8 our tsrget wlth 26 artlcle5 accepted In Its flrst el8ht months. 37 articles submitted 25.974 downloads Extend our relevance and Impact thwough our pollcy and external affairs actlvltles The BSI'S policy and publlc affalrs work have stren8thened si8nbfi¢antl¥ over the past yearto false our proflle and take forward engagements with pollcymakers to brlnB about mean0￿Ul chan8e for Immunology. Achlevements last year Snclude.. Throu8h our Parllamentary Questlons programme, we had 61 wrltten questlons answered, submltted by MPS from all ihe maln politlcal partles. Met wlth nlne MPS and members of the House of Lord5, includin8 Shadow Health and Social Ca Secretary, Jon Ashworth MP, Vaccines Minister Nadhim Zahawi MP. and Lord Bethell. Padiamentary under Secretary of Stste at the Department of Health and Social Care. Also met with many other Indlviduals playln8 a slgnlficant role In the pandemlc response includln8 Deputy Chief Medical Officer, Jonathan Van Tam and Susan Hctpkins, Slrateglc Response Olrector for COVID-19 In Publlc Health England.

Responded to 5 consultation5 on a wlde range of toplr5 In¢ludlng COVID-19 pandemk, research fundln8 and dlversity and Inclusion in sclence. Gave oral evidence to two Select Committee inquiries on vaccine pa55POrt5. Worked with Ihe Mayor of London's office to aware awareness of the importan¢e ol COVID va¢¢ine$ We betame an offitial supporter of the All Party Parllamentary Group on Dlversity and Intlusion in STEM and sponsored thelr report on'Equality in the STEM workforce, Partlclpated In stakeholder network meetln8S With the Royal Society of Bi0108y lincludin8 Parllamentary Llnks Day and Volce ol the Futurel. Assotlatlon of Medlcal Research Charltles, Campalgn for Sclence and Englneerln8 and the Royal Soclety. Focus on CoronavIn￿ and COV11>19 The Coronavlrus outbreak has affected our Ilves In countless ways. From our lobs and research to our wellbeing and the way we connect to our peers. the Immunology communlty has had to rapldly adapt to thls new world. At the same tlme as adlusilng to the pandemlc ourselves we pivoted rapldly to 5UPPOrt our member5 and wider comrnunltle5 wlth respect to the 5clence of the pandeml¢. Reseorchfocus We contlnued our webinar series called 'Conne¢i on Coronavirus, which biings èxpert opinlon and emerglng sclencè from Internationally renowned researchers to our membership and beyond. These weblnars have been hlghly popular wlth up to 1,500 people vlewln81Sve and many hundfeds more ¥lewlrt8 the re¢ordlngs afterwards. They are free and open to all and have been lauded a5 a vltal ￿$0￿1¢e for the ¢ommunlty to maln up to dale on COVID-19 research. Pollcvfocu5 The 8SI worked hard to ensure that the Government recognlses that proper understandlng of Immunolobry Is crlilcal to the Country's response. Most of thls work has been carrled out thfOU8h our COVID-19 expert taskforce, led by BSI Trustee Professor Deborah Ounn-walters, whlch brlngs together IB of UK'S leadln8 Immunologlsts to provlde expert advlce to Input to the BSI'S pollcy work on COVID-19. The key achlevement of the taskforce has been to publlsh three expert reports throu8hout the yeaT"Lon8- rm immunologl¢al health consequences of COVID-19" Yhe aBein8 immune system and COVID-19" and "Immunity and COVIO-19' These were wldely clrculated and made significant impact in in¢reaslng knowled8e about the immune system and COVID-19 amon8St pollcymaker5. The last of these reports was cited by Lord Paiel, Chalr of the House of Lords Sclence and Technology Commlttee, In the House of Lord5, whlch led to meetlng wlth Lord Bethell, the Parllamentary Under Secretary of State at the Department of Health and Soclal Care, respon55ble for Ilfe sclences, research and COVID-19 lon8 term health Impa£ts Lotht.errn iinmun¢logicall hEdl'th consequeKes' CDVIO&.19, The'a9e.inJirnmunE. 5ys¢m'.andlQQVID.19] rfflrntj￿ty &¢Ov1￿19 io

In January. we Issued a ststement around the decision to extend the dosing schedule5 for the COVID vaccines. Thls had a significant effect as at the time there were few expert voices speaklnB Out on the issue. The statement was relerènted by Chief Medical Officer. Chris Whitty, in a live Number 10 pre55 brielbng and eKtensively quoied in the media. From this, we were also invited to provide èn expert briefin8 to the Labour Shadow Cabinet on the issue and to rnèet with Jonathan Van Tam. Deputy Chief Medical Officer. Throu8hout the year, we have engaged extensively with Parllament around COVID-19. providin8 briefin8s for Indlvidual MPS, 8ivlng evidence to the APPG on Coronavlrus, providin8 a back8round briefln6 for the APPG on Blood Cancer on immunosuppression and COVID vacclnes to name but a few. When the COVID vaccines were flrst rolled out. we produced some hlghly popular Q&A sheets for MPS to help them answer potentlal questlons that thelr constltuents might send them aboul CQVID vacclnes. We received lots of posltive feedback on how helpful these were and they a150 led to several face-tO-fa￿ meetin8s wlth MPS. Mor* recently. several other 851 members have given evidence on behalf of the 8SI to different select ¢ommlttee aroLtnd the Immunolo8y underlyln8 the assumptions around vaccine passports. Several of our members have also spoken in pollcy events IncludlnB to the Parllamentary and Scientific Committee. Public engogement En8a8ln8 With the publ1¢ on Immunology Is one of the key aim5 of the BSI and wdve been busy worklng to achieve thls, both through runnlnB public en8a8ement inltiatlvès ourselvès and thro￿￿h providlng 5UPPOTt to our members to bulld their en8a8ement skllls. Ensuring that the public has access to rellable. evlden¢e-based ImmunoloBY Informatlon has become more Important wlth the coronèvirus pandemlc and the need for us all to undergtand the SCIen￿ to make Informed cholce5 about our health. Key actlvltles Included.. Developln8 our hi8hly re8arded'Gulde to VacclnBtlon5 for COVIO-19" a gulde for the publlc to explain how vacclnes work and provlde answers to ¢ommonty asked questlons. We update thls every month to make sure the Information ¢ontalned Is accurate. Thls has received 8reat praise from publlc and experts alike- the Director for Public Health for Hertfvrd5hire called It'by far the most up to date and accurate 8ulde". TV doctor Chrls Van Tulleken sald Thls 8ulde1s a phenomenal piece of work and wlll answer almost any questlon about COVID vaccines". Our 8ui(Je is now Ilnked signposted from 8ovemment sltes Includlng Publlc Health Scotland. IH. Throu8hout ihè yèar. we have run Insta8ram Q&As ￿ allow rnernbers of the publ1¢ to send In questlons about COVID-19 vaccines that are then answered by an expert Immunolo8lst. This has proved very popular and we have received lots of engagement from the public. We have developed numerou5 inlo8raphics to help explain how vaccines work. This Include5 InfoBraphlcs on types of COVIO-19 vaccine, vaccine ingredients, why have the vaccine5 been developed so fast, natural versus vaccine Induced Immunlty, and the immune response after COVID vacclnation. These are now some of the most accessed pages on our webslte and are regularly used by BSI members and the public to help explain to others the sclence behind vaccination. Li

Vaccines VJhat's in a Ipacrine. WatL)r Preservatives and stabilisers Adjuvants We had a partlcular focus on vacclnes, fertlllty and pre8nanty and worked wlth BSI member Vlkl Male to produce a video to answer common questlons on thls toplt. We worked with the Royal Soclèty of Blolo8y to produce explalner videos almed at younger adults on why it was Important for them to get the COVID vacclnes. We worked wlth the Unlvèrslty of EdlnburRh to prodvce several anlmatlons explalnlng dlfferent aspects ol how Immune memory works after COVID Infection and why you need two doses of the COVID vaccines. We have Worked with many or8anlsatlons to help find expert speakers to engage with thelr communllies and answer questlons about va¢clnes. Thls Includes a broad range from worklng wlth the Cablnet Office. dlfferent local counclls. S¢ien¢e Museum etc. We worked with the Mayor of London's office to produce vldeos featurlng our members from dlverse communitles answering ¢¢mmon questions around vacclnatlon. These were put out vla social medla channels and on communSty hubs for use. We collaborated wlth the London BofOU8h of Bexlty and Bexley Voluntary Servlces Council to develop a course on how to have productlve conversations about COVID-19 vacdnes (more detalls below). Took part in online events su¢h a$ Swansea 5cien¢e Fesilval and Dr Jennerfs House Dlscovery at Home to Increase publlc understandlnB around vaccines. In November, we took part In I'm a Sclentlst: an onllne, student-led STEM enrlchment activlty, connectlng students wlth sclent15ts thTOU8h real-ts'me text-based chat5. The BSI part-sponsored the 'Health Zone, with a locus on vaccine immunology. Fifteen BSI members took part and had onllne conversations with school 5tudent5 to answer thebr questions about vaccines and what it's Ilke to have a career 35 a 5clentist. We submlited an activity 10 the 8rbtbsh Science Week a¢tlvlty pack for prlmary school students. We adapted the'herd Immunlty Jenga, actlvlty for thelr'lnnovatln8 for the future, theme. Early evaluation stats are that the pack ha5 been downloaded a total of 52,470 tlmes. 12

We are working with a number of individuals and organisations to translate some of ourvaccine resource5 to make them more accessible to other communities. This includes a number of Widdish translatlons, undertaken in collaboration with the Contemporary Hasidic Ylddish research team at University College London, funded by the Arts and Humanitie5 Aesèarch Council. Other translations are In the plpeline and wlll be released 500n. We collaborated wfth Nature Revlew5 and the Francis Crfck Instltute io puton an onllne event about COVID-19. Wlth high prollle speakers Includin8 Peter Hotez and Teresa Lambe, this event attracted well over I,SOO re8i5tratlons and was well recelved. We produced several info8raphics and accompanylng blog to explain how COVID testln8 works, Includln8 Informatlon on PCR and aTrtlb0￿ tests. Testing for COVID-19 Wliai hoyiKlii¥ wheii yuii K¥1 lill¥ri￿ wlth il* ￿￿￿-(lIv IIT A huge thank you lo all the BSI members who have a55iSted us with these activities.

Engoglng wlth members on COVID-19 vocclnes Our members are all expert Immunologists but they are also mothers. fathws, son5, daughters, trusted friends and members of their communities and that puts them in an excellent position of trust withln thelr networks to have conversations about vaccines to improve publk understandln8. People tan 50mètimès lack thè uJnfidèn¢e to have these conversations so the BSI ran a series of events and actlvities aimed at helpin8 our members to bulld thelr conffidence and enga8Èment skills to have these conversation5. We,. Developed a database of BSI members who wanted to take part in COVID vacclne en8a8ement actlvltles. Th15 ha5 been hugely helpful to us in enabling us to find 5Ultable volunteers for different opportunitles. Ran two webinars for members'Effectlve ways of en8a8ln8 with the publiv and 'Distoverin8 your path to eftectlve publlc en8a8ement" to help provlde members with tralnin8 on how to have effectlve ¢onversatlons about vacclnes. Both weblnaTS had extenslve opportunitie5 to ask questlons to the speakers. Ran our Wa¢¢lne Engagement starts At Home, ¢ampaiBn to provide helpful ttps and advice to members on how to have conversatlons about vacclnes with frlends and famlly Developed a serles of case $tudles of dlfferent a¢tlvltles that BSI members are carryln8 Out around COVID va¢dnes to ertBaBe and Insplre tstheT5 to get Involved. Vaccine engagement day iiiimunolog

Explar•V•ttln•x

14

Medla hl8hll8hts Through our media work. we alm to promote evldence-based and accurate coveTage of Immunology In the news and ensure that joumalists have access to relevant experts who can provide knowledgeable responses. We do this through providiD8 expert comment to breaking new5 stories, worklnB wlth programme researchers to shapeTV or radio broadcasts and through providin8 b3ck8round bdefings. Thls year, our media work has again been dominated by tsso topics which have received very hi8h levels of coverage.. va¢¢lnatlon and COVID-19. The BSI has been a 5trDn8 expert voice on both tOPiC5, ensuring that the expert volce of Immunolo8lsts features promlnently In this fast-movin& complex and high-proflle story. We have worked closely wlth the 5cien¢e Medla Centre thTOU8hout, In¢ludln8 runnlng a number of hS8h proflle media brieflng for national lournallsts. Our coverage has included all malor national news outlets such a5 BBC. ITV News, Sky News, The Tlmes, The Guardian, Daily Mail, Dail¥Tele8raph, Daily Mirror and The Sun. Internatlonal covera8e has included Reuters, CNN, Assoclated Press, Wa5hin8ton Post amon8St many others. 40 BSI press releaselre5pon5e statements 220 artlcles In UK natlonal press I,OOO+ artlcle In worldwlde press P•rtnèr$hlps Workin8 In partnershlp Is core to how the Brlt15h Society for Immunolo8y operates. Immunolo8V touches on numerous dlsease areas and other re$earch dlsclpllnes and is a central plllar of the life sciences and medlcal ecosystem. A5 such, It's Cfltl¢al to our work that we en8age with Ilke-minded or8anisation5 to take lorward our mlsslon and collaborate on areas of common Interest and perspectlve. Growln8 our partnèrshlp portfolio a¢ross all our actlvlties wlll allow us io a¢hleve our strate8lc 8oals and brln8 increased benelils for our members and the dls¢ipllne. Key partnershlps th15 year include.. Connect Immune Research. working wSth IDRF, MS Soclety and Versus Arthrltls and others on autolmmune research. Natlonal Cancer Research Instltute, workln8 to move the cancer Immunotherapy field forward SuppDrtlnB the UK CoronavSrus Immunolo8y Consortlum, a UKRIINIHR funded inltlative to brlng to8ether 20 of the UK'5 leading Immunology research Instltute to Increase our knowled8e of the Immune system and COVID-19 to Improve publlc health London Borough of Bexley and Bexley Voluntary SeNice Councll to provlde a trolnlnB course fry community champlons and health and social care workers on how to have produdlve conversailons about COVID-19 vaccines Mayor of London's office to produce social media assets answerSn8 common questions on COVID- 19 vaccines. International Day of Immunology, workln8 wlth Nature Research and the Francis Crick Instltute to hold a scientific symposium and public event on COVIO-19 vacclne5 Royal Soclety of Bi0108y, en5urinB that the disclpline of biology has a stron8 vobce on the natlonal stage As50Ci3tlon of Cllnical Pathologlsts to run tfainln8 days for dlnlcal ImmunoloBY trainees and Immunology blomedical and cllnical 5cientlsts preparing to sit the Royal College of Patholo8lsts Fellowshlp examlnations. 15

Stlence Media Centre. providing evidence-ba5ed expert response to immunolo8y news stories of national importance Campaign for Science and Engineerin& providing a stron8 voice to Government of the collective views on the sclence and research sector Association of Medlcal Research Charltles, representing the health and medical research charlty seaor on a wider sta8e. Connect Immune Researth Connert Immune flesearch is a collaboration between several charitie5 that support autoimmune research- JDRF, the MS Sotlety, Versus Arthritis and thè Brit15h Society for Immunology. Traditlonally, autolmmune Conditions have been researched and treated in disease-spetlflc silos but underlyin8 tommon immunologlcal mechanism5 have Indicated the benefit of a joined-up research approach. Our partnershlp is designed to brin8 about a crltlcal change In the way autolmmune condltlons are researched, brin8in8 together the dlfferent dlsease areas to facllltate a holned-up approach to 8row fundln8 and fesearch Infrastructure and speed up clinlcal di5¢0very. Thls year, we have added several new organisations to the coalitlon Includlng Alopecla UK and Psorlasis and Psoriatic Arthritls Alliance. We have also undertsken a major new stream of work collaboratinB wlth the Lorn and Yutl Chernajovsky Biomedleal Research Foundatlon. Our alm Is to work together to Pfovide slgnlflcant fundln8 aimed at qulckly developln8 proof of principle for potential new treatments for multlple immune- mediated Inflammatory condltion5 by tar8etln8 pathways common in autoimmunlty. An initlal 5coplng day was held wlth the Immuno108y communlty In May and plans are underway to launch the 8fant scheme In 2021-22. London Borou8h ot eexley and B•¥ky Volunt•ryServl¢e Coundl A partnership between the BSI. london Borough of Bexley and Bexley Voluntary Servlces Coun¢ll dellvered a pilot programme to train champions within local communlty leaders and healthlsoclal care workers to have effective conversations with thelr Detworks and peers, answering questlons and concerns about COVID-19 vacclnes. The training was co-designed with 2 different groups Icommunlty leaders and health/social care workers), and conslsted of l-hour online sessions each week IOT S weeks. The session5 were led by Immunologlsts skllled at en8a8emeni, with appearances from local falth leaders and healihcare professlonals. The content focused on bulldln8 understandln8 of vacclne5. as well as developln8 5k1115 on li5tenlng to and answerln8 questlons and conterns. Sesslons WÈ￿ user-led. addresslng toplcs ralsed by pèrtltlpants and their communitles. 80th groups had po51tive experiences. 100% of ¢ommunity leader5 strongly agreed or agreed that they felt better Informed. more knowledgeable, and conlldent to have effective conversatSons as well as reportln8 that they Increased the number of people they talked to about COVID-19 vacclnes. 92% of healthcare workers 5tron8ly agreed or 38reed that they felt better informed and mtsre knowledgeable about COVID-19 vacclne5. whlle 85% strongly agreed agreed that they felt more confideni about having effectlve tonversatlons. 70% of healthcare workers agreed of stron8ly agreed that they had increased the number ol people they tslked to about COVID-19 vaccines. Workin8 in partnership was key to 5ucces5 of the project In reachlng people on the front line who hold social capltal and thu5 increased the impact of the Pfoject. UK coro￿vIruS ImmunoloBy Consortlum The UK Coronavirus Immunology Consortium IUK-CICI Is a natlonally targeted effort to understand the Immunology of SAR5-CoV-2 and COVID-19. Thls prolert has recelved £6.5 mlllSon of funding over 12 months from UK Research and Innovatlon IUKAII and the Natlonal Instltute for Health Research INIHRI, and involves leadlng immunologlsts Irom 20 ¢entres of excellence around the UK. 16

cic UK Coron•¥Sius Immunology CoDsortlum The British Society for Immunology was a supportln8 partner of UK-CIC throughout its 12 months of ftjnding. BSI PresldenL Professor Arne Akbar, acted as chair of the UK-CIC Scientifi¢ Advisory Board, which dellvered Independent overslght and input to St5 Strate8ic prSoritie5. The BS1 also prgvided seeretarlal servlces to thls board, includlng orRanlslng the agenda. arranglrwd presentatSons Irom UK-CIC researchers, and provldin8 mlnute5 after each meetln8. The 8SI also Implemented the Patlent and Publlc Involvement IPPII pro8ramme, sourcltvd a panel of representatlves that ofleied unlque insl8hts and per5pective5 on UKQIC research. The BSI or8ani5ed regular meetin85 Wlth the PPI panel, with slrnllar admln15tratlve support to the S¢lentlllc Advisory Board meeting5. We have also worked wlth the PPI panel on several publSc engagement actlvities including research Summaries, webln3rs, vldeos, and on a formal manuscript on PPI involvement In UK-CIC researth. The BSI ran ¢ommunl¢atlons for UK-ac to engage wlth fesearcher5, the publlc, and pollcy maker5. Thls Included Internal and external communlcatlon5, medla engagement, the webslte luk-¢l¢.orgl and so¢lal medla. 7hls also included the fla8ship vlrtual conference for VK-CIC, 'Collaboratlve Covld Immunolo8y, whl¢h the BS1 or8anlsed, promoted, and dellvered. Internatloffal V•t•rln•ry V•cdnolo8y Netwofk IMIN} The BSI published a joint report with the IVVN to revlew the current state olthe veterlnary vacclnolo8V landscape and set out the key recommendallons to malntaln the UK'S leadln8 role In thls area. r)iver%lfy ¢)Iir lne.ome It is essentlal lor the SocIe￿9 lon8-term sustalnabillty that we dlver51fy our income throu8h the enhancement ol current income 8eneratin8 activilies and the creation of new income stream5. In November 2020 the Soclety launched its flrst new 5ournal In over slxty yeaTS. It has met its initial performance targets and Is hoped to 8row sbgnificantly over the next few yeaTS. The Society Increased the number of approaches made to funders resultlng In a r15e of grants and donatlon5 recelved. Thls work wlll contlnue next year. The trustees increased the Sociews long temi sustalnabllity fund to £250k to resource the development ol new intome source5 to ensure the lon8 term sustainability of the Society. 17

Strurture, Governance and Management C￿lIt￿ble st•tUs Jnd ¥dministrnti¥e détsils The Society was re8iStered as a charity in 1966 (Charity number 10432551 and intorporated in England and Wales 35 a company, Ilmited bv Buarantee (Company number 030059331. The Sociews re8iStered address is Devonshire House, 60 Goswell Road, London ECIM 7AD. It ha5 no share capital and the liability of its member5 151Smited to a sum not exceeding £1. The Society's 8overnln8 do¢ument Is the Mèmorandum and Artlcles of Assotlatlon. whlch was amended on 7 December 2016. It is a150 a registered charlty In Scotland Ichaflty number SC0473671. Board of Trustees The Trustees are company dlrectors for the purposes of the Companles Act and charltyTrustees for the purpose5 01 the Charitle5 Act 2011. The current trustees, and any past Twgtee5 who served durlng the year are Ilsted on pa8e 51. The Trustees are responsible for directin8 the Socie￿5 activlties and for overseein8 the management of the ffalrs of the Soclety, they dele8ate the day to day mana8ement of ihe organlsatlon to the chlef executlve and the senlor mana8ement team. The Board acts on advlce and Information from regular meetin8s wlth the chlef executlve and the senlor mana8ement team. As part of thelr Inductlon process, Trustees spend some tlme at the Soclet¢5 offlce, wlth the chlef executlve and staff. They are provided a trustee resource pack containin8 the hlstory of the So¢lety and key Infomiatlon they require lo fulfll their duties a5 Trustee, they are al$0 offered trainln8 for new Trustees. The success of the Soclety belongs In part to the lar8e number of people who generously volunteer thelr tlme to add thelr experlence to our collectlon of commlttee5, we thank you all. Fln•nt¢ Sub Commlttèe The Flnance Sub Committee ensures the systèm of Internal control Is satlsfadory to dellver regulatory ctsrnpllante, flnan¢lal problty. value for money. thallenge of flnancial plans, budgets and financlal statements. oversS8ht of the annual finandal audlt, revlew of Investment poll¢y and performancè. revlew of reserves pollcy, and CEO and staff renumeratlon. Nomlnatlons Commlttee The B51's Nominatlons Commltteè has general ovefsl8ht concernSng the structures and effectlveness of BSI Board of Trustees, commlttees, adv15ers and observer5. It Is also respon51ble for nomlnating indivlduals to represent the views of the BSI on external ¢ommittee5 and to Identlfy B51 members to nomlnate for external wards. Forum The Forum represent5 a diverse mix of irnmunolo815ts from diflerent career stages, backgrounds and geographic loc3tion5, It is responslble for developln8 pollcy and advlsln8 on communlcatlons, educatbon and publlc engagement work. Congress Committee The Congress Committee is fespon5ible forthe plannln8 ènd dellvery of thè BSI'S flagship evenL B51 Congress, whlch tskes place two out of every three years. It revlews and approves the sdentific programme for Con8ress.

Cllnical Commlttee The ainlcal Commlttee represents the wider tllnl¢al Immunology and aller￿ communbty and alms lo enhan cornmunicatlon between sclentlflc and clinlcal ImmunoloK¥ communitles. Group structure The Society has one wholly owned subsldlary.. BSI Tradin8 Llmited is registered in the UK under company reglstration number 010201739. Its prlncipal actlvlty Is to manage the ¢orporate mèmbershlp, sponsorship, exhibition and other tradlng actlvities for the Society. This primarily comprises exhibition and swjnsotshlp for the BSI Corwe55. Flnanclal Performance Thls year been challenBln& however the 851 team worked In¢redIb￿ hard to dellver a very strong financlal perfomiance. Net Income dlmbed to £0.87m from EO.17m last year. Congress was postponed due to COVID-19 restrictions- however, we dellvered the BSI'S first ever virtual conference. Our journals remain our largest Income stream, this was bolstered thLs year with slgnln8 bonusès for our new journal Immunotheropv Advonce5 and for the new publishlng contract for Clinlcul & Experlmentollmmunology. The So¢let￿5 d1vers1fi￿tlOn of Income ¢ontlnved wlth an Increase In grants and donatlons. Total income 2021 ££££££££££££££££££££££££££££ £2.19m £££££££££££££££££££££££££££££ £2.23m 2020 COVID.19 had a $18nlficant Impact on the socletvs actlvltles durlng the year,. the postponement of Con8ress led to a reductlon In total ¢osts. Costs ift other areas a150 fell a5 actlvities were elther postponed or dellvered In another form. Travel restrictions also resulted In the wlthdrawal of our travel grants. The soclety spent £161k supportlng the UK Coronavlrus Immuno108y Consortlum IUK-CICI, a twelve month prole¢t to brinB together Imrnunology research on COVID-1g. Thls was work was funded by a 8rant from UKRI and NIHA. The postponement of Congress had an Impact on BS1 Tradlng Umlted, although the finan¢lal suttess ofthe vlrtual conference Ilmlted thè redurtlon In Income to 5796. The company posted an annual proflt of £0.12m 12020.. £0.31ml. Thls was glfted to the 50¢iety. The so¢leVs Investment portfolio provlded solid Income In line wlth 2020. The value of the portFollo rose by £0.51m produ¢lng its besi annual performance. On 30 lune 2021 Investments were valued at £4.45m. Reserves rose to £4.94m, contlnulng thelr ￿se fr(Nn £3m flve year a80. The BSI also had a year-end cash balance of over £lm forthe third consecutlve year. Investmen

The tentral role of Immunology In unc￿erIng the Impact of COVID-19 on the Immune system and Into research for treatments and a vaccine puts the BSI in a relatively good positlon to secure future fundlng to Continue thè So¢ietVs work supportlng the Immunology tommunity durlngthls pandemit and beyond. Investment poli¢y and perfornmnce Thè Society operate5 an investmènt policy to 8eneratè capital 8rowth. The high levels of volatlllty resultlng from the COVID.19 pandemlc, contlnulng UK and 8lobal polltlcal ncertainty create5 a challenglng environment In which to manage Inve5tment5. The Society is a lon¥-term Investor and the value of Its Investments remalns slgnlfi¢ant above Its ortglnal Investment. Funds are Invested wlth Aberdeen wlth a long-term oblectlve to generate a rapltal return of 3% more than Inflatlon over a three year rolllng period. Performance was exceptlonal generatlng net gains ot£O.Slm for the year12020.' £0.Ilml. The Flnance Sub Commlttee Is responslble for revlewln8 Investment performance and pollcv. Rès•p4•s pollty The BSI operates a rlsk-based approach to reseNes to ensu￿ the BSI holds the most appropriate level ol reseNes to cover potentlal rlsks and to fund Invest In new Income sources securlng the BSI'S long term financial health. The f15k re815ter Is revlewed annualty wlth monetary values allocated to 5peclfic risks, re5trlcted and desl8natÈd funds. A provision for unknown risks Ito give cover for those ri5k5 of whl¢h the Society is not yet aware) Is calculated based as a per¢*nta8e of the rlsk adjusted fund. The latesi review resulted In total requlred allocated reserves of £2.93m12020.' £2.89ml. On 30 June 2021 total reserves were £4.94m, Includlng free reserves18eneral reserve5 less flKed a5set51 of £3.82m 8lvln8 an exces5 over the tar8et of £0.89m12020'. £0.86ml avallable for use by the Soclety to further Its 5trateglc alms. Detalls of regtrtaed funds can be fo¢Jnd In note 17 of the accounts with detalls of designated funds In note 18. The calculatlon ol the total required allotated reserves Is performed on an annual basls. Pay poll¢v Salarles, Intludin8 Key Mana8ement Per50nnel, are revlewed by the Finance Sub Commlttee wlth re¢ommendatlons for the annual pay rlse proposed to the wlder Boaid of Trustees for appfoval as part ol the annual budgetln8 process. The salary of the Chlef Executlve15 revlewed annually by the Board of Trustees. R15k mana8emÈnt Good rI5k mana8ement is fvndamental to the ¢ofttlnued work and 5UStainablllty of the So¢lety. We identify and man8e rbsks that could adversely Impact the achlevement of our strateglc purpose and determlne the calculated rlsks we need to take to succeed. The Soclety operates a formal framework for the management of rbsk, taklng the vlew that rlsk can be posltlve lopportunltyl or ne8atlve Ithreatl. The Sodety operates a rlsk re8lster Incorporatln8 Strategla operational and complian¢e risks, which are inft>rmed by the SocletV5 Strate8i¢ objectlves, performance, volce of our stakeholders, regulatory environment and ana￿$15 of the external enwronment. The Board dele8ates day-to-day responsiblllty for rlsk management to the Sensor Management Team, who are re5pon5ible for identifyin8 and evaluatin6 risks to their areas and activities implementing approprlate controls for ongolng mltigatlon and monltoring. The Financial Sub Committee review5 the management of r15k in detail at each meetin8 and the Board reviews the Soclety's strategic and compliance risks twice a year.

The malor rlsks faclng the soclety and the mltlgatlon that we have put In place are as follows.. Rlsk Rlsk response Fallure to dlversify our Income The SocSety Is lookln8 at opportunltles to dlverslfy Income includlnB: Working wSth partner5 to develop Important relationships with funders dellvering increased grants and donatlon5 Implementlng a fundralslng strategy to develop new In¢ome streams The Soclety Is heavlty rellant on a single source of income.. journals. Lon8er-term reduced intome Irom the BSI portfollo of journa15 The Society has Oeveloped 3 Ptan wlth our publlsher to Ilmit irhy flnanGlJl loss on the move to Open Access The move to open acce55 will impad the Income re￿Ived from the Society's journals. Inflationary price Increases may be Ilmlted post-pandemlc Worked wlth a publlshlng consultant to assSst wlth negotlatlons w+th our publlsher to secufe the best financlal outcome in new contracts Launched new journal Poor handlln8 01 8o¥ernmenVfundlni b￿Tres relatlons The Soclety wlll contlnue to.. Ensure Bood Forum and Presldent oversl8ht of our statements, slBn-off of sensltlve letters vla President or another irvsiee. Insensltlve handllng of Issue5 such as vacclnes or animal research could leave BSI wlth poorer reputatlon Ensurè SMT distuss all $18nlfi¢ant Poll¢y and Publi¢ Affalrs Issues Adverse commentary. publlclty QT acllon or poor publlc perceptlon The So¢lety will contlnue to: All staff, tru5tee5 and volunteers who perform medlalwebsliel pollcyl publlc engagement work on behalf of the BSI are properly tralned and aware of publlc's vlews CEO oversees and dlscu55es controver51al i55ue5 Wlth tru5tee5 before releasin8 publi¢ statements Publlc do not know much about the BSI but the T15k would be twofoltl.- that we do not talk about Issues of importance to members, or that we misrepresent thelr vievJ3 Fundralsln8 Statemgnt Althou8h the Soclety does not actlvely fundralse from members, occaslonal donatlons are recelved. The Society applbes best practice in the tone of It5 communicatlons and the accuracy of it5 data to minimise the pressures on supporter5. The Society applies best practice to protect supporters, data, never sells or swaps it and ensures that communlcatlon preferences can be changed at any ilme. The Soclety commlts to react to and investigate any complaints received, to learn from them and improve its servlce. Durin8 the year, the Soclety re¢elved no wmplaints about it5 fundraisin8 artivities. 21

Future pl•ns The trustees have approved a new five year stfategy commencin8 ju￿ 2021. The new strate8ywas developed through consultation with stalf. trusteès, BSI Forum members, Secretsrie5 and editors buildin8 on work from the previous six years. The new strategy Includes a wlslon statement.. "Better health for all through Immunolorf And an updated m1s5ion 51atement'. Ie are ¢ornmltted to suppryllnl our Immunoloyi communlty In drmni scl•ntlfk dlsco¥ery and to make a posltl¥e Impart on health" The strate8y Is based upon three plllars Connected Communlty, Careers, Catalysln8 Chan8e and our underpinnln8 priority.. Enablers •irh MpDpJrllowTkpMbblto *f As part of our strote8V the BSI has developed a Set ol BS1 values whlth underpln all soclety a¢tlvlties.' We are.. AmbltiOUS lind commltted Evidence-ba5ed and responslble Collaboratlve and Incluslve Aglle and energetlc

The activltie5 for 2021-22 wlll focLSS on.. Pillar I.. Connected Community Deliver a successful Congress 2021 Deliver a new BSI awards ceremony Plllar 2.. Careers To successfully Increase the careers support the 6S1 provldes to member5 Plllar 3.. Cataly5in8 Chan8e To bulld the 851's partnershlp portfol50 and Impact To continue the BSI'S successful programme of vaccine work. Underplnnlng Pflority= Enablers Dellver a Journals strategy, ensurlng optlmal flnan¢lal performance from exlstln8 and newloumals Launch refreshed rnembershlp offer Oevelop and launch new CRM system Smooth transitlon io hybrld worklng The majorlty of BSI income is derlved from our lournals. To date, the submlsslon of papers and journal subs¢riplions have not been siqnillcantly affected by COVID-19. The Senior Management Team and the Trustees contlnue to assess the Impact of COVID-19 on the Soclety, tO8ether wlth all other si8rtlfl¢ant risks, in the immedlate, medlum and longer term. Th15 Includes the BSI team's ways of workln& our flnanclal reoulremenis, all Income streams and the perlorrnance of Investments. Trwt*es' responslbllStl•J The Trustees (who are also d1￿ctorS of 8Atlsh Soclety for Immunolo8y for the purposes of company lawl are responsible for preparSng the Trvstees, report and financial slatements in auordance with appllcable law and Unlted Klngdom Accountln8 Standards (United Kirt8dom Generally Accepted Accounting PractScel. Company law requires the Trustees to prepare linan¢lal statement5 for each flnènclal year whlch glve a true and lalr view of the stste of affalrs of the Group and Soclety and ol the Inujme and expendlture of the Group and Society for that perfod. In preparln8 these flnènclal statements. the Trustees are requlred to.. select sultable accountlng poll¢les and then apply thern consi5tentlv,' observe the method5 and principles in accountin8 and Reportlng by CharStles'. Statement of Recommended Practice appllcable to charltle5 preparin8 their accounts in accordance wlth the Flnancial ReportSng Standard appllcable to the Unlted Kln8dom and Republic of Ireland,. and make judgements and estlmaies that are reasonablè and prudent; slate whether appllcable Unlted Klngdom Accountlng Standards have been followed. 5ublect to any material dèparture5 disc105ed and explalned in the financlal statements,. and prepare the financial statements on the 8oln8 concern basts unless It Is inappropriate to presume the charlty will continue in operation. 23

TheTru5tees a￿ responslble for keeplng proper ac¢ountln8 records that di5c105e with reasonable accuracy at any ts'me the financlal posltion of the Group and Sodety and enable them to ensure that the ffinantial statements comply with the Companie5 Act 2006. They are also responsible for 5afeguardin8 the assets of the Group and Society and hence for taking reasonable steps for the Pfèventlon and detectlon of Iraud and other irregularities. Each of Trustees conflrm that.. so far as theTrustee Is aware, there Is no relevant audit InfoTmatlon of whkh ihe Group and Socie￿$ auditor Is unaware; and the Trustee has taken all steps that helshe ought to have taken as a Trustee In order to make himselflherself aware ol any relevant audlt Informatlon and to establlsh that the Group and Sotlevs audltor is aware of that infomation. Thls confirmatlon 15 Blven and Should be Interpreted In accordance wlth the provlslons of s418 of the Companles Atl 2006. The Trustees are responslble for the malntenance and Integrlty of Corporate and flnanclal Informatlon Included on the SocIet￿5 webslte. Leglslatlon In the Uniied Kln8dom governingthe preparatlon and d15semlnatlon of flnan¢lal statements may dlffer from le8lslatbon In other lurlsdictlon5. Approved by the Trustees and sbgned on thelr behalf by.. Arne Akbar BSI Presldent Oale..

Independent Audltorfs Report to the members and trustees of the British Society for Immunologv Oplnlon We have audited thefinancial statements of the British Societyfor Immunolo8yfor theyear ended 30 June 2021 which comprise the Group Statement of Financial Activitie5, the Group and Parent Charitsble Company Balance Sheets, the Group Cash Flow Statement and notes tothe financlal statements, includin8 a 5ummaryof 5i8nificant accountin8 policies. The financial reportlnB framework that has been applled In thelr preparation is appllcable law and Unlted Klngdom Accounting Standards. including Flnancial Reporting Standard 102 The Flnanclal Reportin8Standard applicable In the UK and ftepublicof Ireland Iunlted Klngdom GenerallyAc¢epted Accountln Prartlcel. In OUT oplnlon the flnanclal statements.. glve a true and fair vlew of the state of the 8roup'5 and the parent charltable compan(s affalrs as at 30 J(tne 2021 and of the group's Incomin8 resources and application of resources. Intludin8 lis income and expenditure. for the year then ended,. have been properly prepared In accordance wlth Unlted Kln8dom Generally Accepted Accountln8 Practlce., and have been prepared In attordance wlth the Companles A¢t 2Crf)6, the Charltles and Trustee Investment (Scotlandl Act 2C4)S las amended), regulatlons 6 and 8 of the Chariiles Accounts (Scotlandl Regulatlon5 2006 las amendedl and the Charltles Act 2011. lsfor oplnlon We conducted our audit in accordance with International Standards on Audltin8 IUKI IISASIUKII and appllcable law, Our responsibilltles under those standards are further descrlbed In the Audltorfs Responsibilltles for the audlt ol the fln8ncial statements sectlon of our report. We are Independent of the charltable company In accordance wlth the ethlcal requlfements that are relevant to our audlt of the finan¢lal statements in the UL ncludlng the FRC'S Ethl¢al Standard, and we have fulfilled our other ethlcal responslbllltles in accordance wlth these requlrement5. We believe that the audlt evldence we have obtalned Ss sufficlent and approprlate to pfo¥lde a bas15 for our oplnlon. Concluslons relatln8 to yln8 ¢on¢•m In audltln8 the financlal statements, we have concluded that the trustees, use of the 8oln8 ¢on¢em basls of a¢¢ountln8 In the preparalion of the financial statemenls 15 appropriate. 8ased on the work we have performed, we have not Identlfled any materlal uncertalniles relatln8 to events or ¢onditlons that. indlvidually or collectlvely, may cast sl8nificant doubt on the charltable company's ablllty to contlnue as a golng con¢em for a perlod of at least twelve month5 from when the financlal statements are authorlsed for Issue. Our re5ponslbillties and thè responslbllitles of the trustees with respect to goin8 ¢oncern are descrlbed in the relevant sections of thls report. other Informatlon The other informatlon comprlses the Informatlon Included In the annual report, other than the frnancial statements and ouraudiiorfs reportthereon. The trustees are responsiblefor theother information. Ouropinion on the financial statements does not cover the other information and. excèpt to the extent otherwtse explicitly Stated in oui report, we do not express any form of assurance concluslon theieon. 25

In connectK*n with our audit of the flnandal statements, our responsiblllty lsto read the other Infomiatlon and, in dolng so. conslder whether the other information is materially inconsistent with the financial statements or our knowledge obtained inthe auditor other¥•Jise appears to be materially misstated.11 we Identify suth materia5 inconsistencies or apparent material misstatements, we are required to determine whether there is a materlal misstatement In the flnantial statements or a material mlsstatement of the other information. 11. based on the work we have performed, we conclude that there is a materlal misstatement of this other informatlon, we are requlred to report thatfact. We have nothlng to report In thls reBard. Oplnlons on other matter5 PTexrfbed by the Companles Act 2006 In our opinion, based on the work undertaken in the course of the audit.. the Informatlon 8lven In the tru5tees' annual report for the flnancial yearfor whkh the flnanclal statement5 are prepared Is conslstent wlth the financlal statements,. and the trustees, annual report have been prepareil In accordance wlth appllcable legal requlrements. Matters on whlth w• am req￿rnd to r•port by •Mceptlon In the Ilght of the knowledge and understandSng of the 8roup and parent charltable company and its environment obtained Sn the course of the audlt, we have not Identlfied material mlsstatements In the trustees, nnual report. We have nothlng to report In Tespert of the followln8 matters where the Companle5 Act 2006, the Charltle5 Aecounts Iscotlandl Regulatlons 2006 las amended) and the Charltles Act 2011 requlre us to report to you If, In our oplnlon: the parent charitable compony ha5 not kept adequate and 5ufflclent accountlnB records, or return5 adequate for our audit have not been receSved from branches not vlsited by us,. or the parent charltable company's linanclal Statements are not In a8reement wlth the accountlng records and retum5,' or certaln dlsclosure5 of trustees, remuneratlon speclfled by law are not made; OT we have not ￿CeIved all the Informatlon and explanatlons we requlre for our audlt,. or the trustees were not entitled to prepare thè financlal ststements In accordance wlth the small Compènles regime and take advantage of the small companleg exemptlon In preparlng the Trustees. Annual Report and from preparing a strategic report. R•spon51blllll•J of trust••5 As explalned more fully Sn ihe trustees. resp¢nslbllltles statement, the trustees (who are also the directors of the charitable company for the purposes of company lawl are responslble for the preparatlon of ihe financlal Statements and for bein8sat15fied that they give a true and falT vlew, and lorsuch Internal control as the trustees detevmine Is necessary to enable the preparation of financial 5tatement5 that ore free from material mlsstatement, whether due to fraud or error. In preparingthe flnanclal statements, the tfU5tees are responsible for a55e5s1n8 the group and parent charitable company's ablllty to contSnue as a going concern. di5c105in& as applic3ble, matters related to Boing concern and Using the 80in8 concern basls of accountlng unless the trusiees elther Intend to Ilquldate the group or parent charltable Company or to Cease operations, or have no realistic alternative but to do so.

Audilorfs responsibllitieslor the audit of the fin¥nci•l 5tstements We have been appointed as auditor under Section 44llllcl of the Charities and Trustee Investment Isctstlandl Act 2005. the Companies Act 2006 and Section 151 of the Charities Att 2011 and report to you In accordance wlth regulations made under those Acts. Our oblectlves are to obtaln reasonable assurance about whether the flnanclal statements as a whole are free from materlal mlsstatement, whether due to fraud or error, and ￿ Issue an audltorfs report that Includes our opinion. Reasonable asstsrance is a hlgh level of assuran¢e. but is noi a guarantee that an audlt conducted In accordance with ISAS IUKI will always detect a materlal misstatement when it exlsts. Mlsstatements can arlse from fraud or error and are considered material if, individually or in aggregate. they wuld reasonably be expetted to Influence the econom1¢ declslons of users tsken on the basls of these flnan¢lal statements. Irregularities, includingfraud, are instancesof non-comp11an￿ with law5 and regulations. We de518n pro¢eduTe5 in Ilne wlth our responslbllitle5. Outlined above, to detect material misstatements In respect of Irregtslarlties, Includlng fraud. The extent to whlch procedures are capable of detecting Irre8ularltles, Includin8 fraud Is detalled below. Expl•n•ilon •s to what ¢xt•it the audlt w•s ¢onsld•r•d capabk ol d•t•£t1￿ Irr•8ularltl•s. IncJdlng fraud The oblectlve5 of our audlt In respert of fravd, are.. to Identlfy and a55e5s Ihe rlsks of materlal mlsstatement ol the flnancial statements due to fiaud,. to obtain sufficlent appropriate audlt evldence regarding the assessed risks of material misstatement due to fraud, throu8h de518nin8 and implementln8 approprlate re5pon5e5 to those assessed rlsks. and to respond approprlalèly to Instances of fraLtd or suspected Iraud Identlfled during the audlt. However, the prlmary responslblllty for the preventlon and detectlon of fraud rests wlth both management and those charged wlth governance of the charStable companv. Our approach was as follow5.. Wè obtalned an understandlng of the legal and regulatory requlrements appllcable to the charltable company and consldered that the most $18nlflcant are the Companles Acl 2006, the Charitses and Trustee Investmeni (Scotlandl Act 2005 las amended), fe8ulations 6 and 8 of the Charities Accounts Iswtlandl Re8ulatlon$ 2006 las amended). the Charitie5 Act 2011, the Charity SORP, and UK financial reportlng standards as Issued by the Flnanclal Aeportln8 Councll We obtalned an understsndln8of how the charltablecompany complles wlth these requlrements by dlscusslons wlth management and those charged wlth governance. We a$5e55ed the ￿sk of materlal m155tstement of the ffinan¢lal ststements, Indudlng the rlsk of materlal mi55tatement due to fraud and how It ml8ht occur, by holdlng dlsctssslons wtth management and those charged with governance. We inquiied of management and those Charged with governance as to any known Snstsnces of non-compllance or suspected non-compllance wlth law5 and regulatlons. Based on this understandln& we desl8ned spe¢lfi¢ appropriate audit procedures to Identlfy Instances of non- Compllance wlth laws and re8ulatlons. Thls Included maklng enqulyles of management and those charged wlth governance and obtalnlng athjltlonal corroboratlve evldence a5 requlred. As part of an audit in accordance with ISA5 IUKI we exerclse professbonal judgement and malntsln professSonal sceptlclsm throughout the audit. We also: 17

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those rlsks. and obtain audlt evidence that is sufficient and approprSate to provide a basi5 lor our opinion. The risk of not detectin8 a material misstatement resultin8 from fraud Is hi8her than for one re5ultin8 from error, as fraud may Involve collusion, forgery* Intentional omlsslons, mi5repre5entatlons, or the overrSde of Internal control. Obtaln an understandlng of internal control relevant to the audlt In order to deslgn audlt pro¢edure5 that are appropriate in the circumstances. but not for the purposes of expresslng an opinion on the effertlveness of the group and parent charitable company'5 Internal control. Evaluate the approprlateness of accounting policie5 Used and the Teasonableness of accountin8 estimates and related dlsclosures made by the trustees. Conclude on the approprlateness of the trustees. use of the goln8 concern basis of accountlng and. based on the audlt evldence obtained, whether a material uncerlalnty exlsts related to events or condltions that may cast slgnlflcant doubt on the group and parent charltable companvs abillty to contlnue as a goln8 contern. If we conclude that a materlal ￿n￿rtaInty exists, we are required to draw attentlon In our auditor's report to the related dlsclosures In the financlal statements or, If such dlsclosures are Inadequate, to modlfy our oplnlon. Our conclu51ons are based on the audlt tvldence obiabned up to the date of our audltorfs report. However, fvture events orcondltlons may cause the group or parent charltable companytoceaseto contlnue as a going concem. Evaluate the overall presentatlon, structure and Content of the fSnan¢lal statements, In¢ludlng the dIs¢l￿u￿$, and whether the financial statements represent the undedying tran5aCiions and events in a manner that achieves fair presentation. Obtain sufliclent appropriate audlt evidence regaidln8 the flnanclal Informailon of the entltles of buslness actlvlties wlthln the 8roup to express an oplnlon on the consolldated financial statements. We are respon51ble for the dlrectlon, supervlslon and performante of the group audlt. We remaln solety responslble for ouf audlt report. We communlcate wlth those charged wlth governance regardlng, among other matters, the planned scope and tlming of the audlt and signlficant audlt flndlngs, Sncludln8 any sl8nlllcant dehclendes in inteinal control that we Identlfy duTin8 our audlt. Us• of our report Thi5 report Is made solely to the charltable companrfs members, as a body. In accordance wlth Chapter 3 of Part 16 of the Companles Act 2006,. and to the charlty's trustees, a5 a body. In accordance wlth Sectlon 44llllcl of the Charlties and Trustee Investment Iscotlandl Act 2005. and In respect of the con501idated financial staternents, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work ha5 been undertaken so that we mi8ht state to the charltable companws members and trustees those matters which we are requlred to state to them in an auditorf5 report and lor no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party oiher than the Charitable ¢ompany. the charitable Company's members, a5 a body, and the charity's trustees, as a body for oui audit worK for thls report, or for the opinlon we have formed. J.A LL¢ Date 1911012021 Neil Finlayson (Senior Statutory Auditor) for and on beholf of Moore Kingston Smith LLP, Statutory Auditor Devonshlre House 60 G05well Road London ECIM 7AD Moore Klngston Smlth LLP Is ellglble to act as audltor In terms of Sectlon 1212 of the Companles Act 2006. 28

British Society for Immunologv Consolidated Statement of Financial Activities Yearto 30 June 2021 Unrestricted funds General funds Desl8nated funds Restr￿ed funds £'ooo Total 2021 £'ooo Total 2020 £'ooo Note Income from: Grant$ and donations Investments Charitable actNtties Membership Partnershlp work Congress Meetin8s and events Journals Total Income 188 190 113 loo 112 113 145 78 145 78 170 61 464 46 1,282 2,235 ios 1.552 1,995 1,552 2,186 191 Expendlturn on.. lalsln¥lunds Investment management fees Cost ol raising funds ChaTlt•bl• actlvltl•s Membershlp Awards and 8rants Congre$5 MeetlnRS and events Publlcatlons Bnd journ815 PolScy ond PublSc Affalfs UK-CIC Partnership work Educatlon and CBreer5 Public en8a8ement Cornmunlcatlons InternatSonal work Total •Mp•ndltur• 36 13 36 13 33 12 156 25 166 253 377 176 156 25 166 253 377 181 161 118 67 73 169 32 1,827 183 136 587 267 358 190 161 31 87 62 73 146 32 1,602 75 86 213 36 2,177 23 223 N•t Income le¥peDdltur•l b•for• 8alns Ilossul on Inve51rnents and transfers Net 8aln5111ossesl on Investments Transfers between funds Net Income/ldeficltl 393 1321 359 57 12 507 507 iio 738 162 738 736 1321 167 RecoDclNatlon gllund$: Funds brou8ht forward 3,771 250 57 4,078 3.911 Funds carrled forward 25 4,078 There are ￿ recognised gain5 or b55e5 Qtherthan those recognised above. All actfvities are continuing. The notes on PBges 32 to SO form part rrfthe5efinancial 5t8ternents

British Society for Immunologv Balance Sheet 30 June 2021 Group 2021 Charity 2021 2020 2020 Flxed assets Tan8ible fixed assets Intangible assèts Investments li 12 13 18 37 4,454 13 18 37 4,454 4.509 13 3,871 3,884 3,871 3,884 Current assets Debtors Cash at bank and Sn hand 14 130 1.227 1,357 122 1,037 1.159 264 1.079 418 69G 1,114 Llabllltl•s: Credltor5.' amounts fallln8 due within one year Net ¢urrent •y•t£ 15 19221 435 19651 194 19081 435 19201 195 Net a55ets 4,078 4.078 Funds., Unrestrlcted lund5 General fund Oe5i8nated fund 3.933 986 4,919 25 3,771 250 4,021 57 3.933 986 4,919 25 3,771 250 4,021 57 18 Restrlcted fvnds 17 Total 4,078 4,078 These financlal statements have been prepared In accordance wlth the PTtsvIsion5 appllcable to the small companies re8lme. These accounts were approved by the Board and authorlsed for Issue on l signed on it5 behalf by.. '¥ ( and were Arne Akbar, Presldent British Soclety for Immtsnology. Company Limited by Guarantee Comp8Try Re￿$tratIc1n Number 03005933 IEngland and Wale51 The notes on pages 32 to 50 form part of these flnanclal statements

British Society for Immunology Consolidated Statement of Cash Flow5 30 June 2021 2021 2020 £'ooo Cash Ilows from op¢ratlng *ttfrthles'. Net cosh provldedby operatlng Ortlvlties 203 1118 Cash Ilow$ from In¥estln8 ¥Ctl¥ltles'. Incorne from investments 113 112 Purchase of tangible flmed assets Proceeds from the disposal of Investments Purchase of investments Iiii 599 630 15951 105 18361 11051 N•t ¢a$h us•d In Inv•gtln8 aCtl¥ltl•s Chany In cash •nd cash •qufvabents In the y•ar Cash and cash egulvalents at l July 2020 270 33 1,215 1.182 C•5h and cash equbvjlents •t 30 Jun• 2021 1.485 1,215 N¢t In¢om¢ for lh• p•rlod las p•r lh• stat•m•nt of Ilnanclal actlvltks) Adlugtments ￿. Depreclation char8e (Gain51 on investments Investment income 167 15071 11131 181 1441 zoy iiioi 11121 49 Ilncreasel decrease In debtors Increase In crtditor5 11201 11181 Nét cash provlded by operatln8actl¥ltles Analysls ol cash and ush equlval•nts Cash at bank and in hand 1,227 258 1,037 178 Cash held by Investmeni manageis Total ro5h ond cash equlvalents 1,485 1,215 The notes on pages 32 to 50 fomi part of theseflnanclal statements 3J

Notes to the financial statements Accountln8 pollcles The prlntSple accounting policies adopted, judgements and key sources of esiimatlon untertalnty in the preparation of the financial Statements are 35 follows.. Bas15 01 pr8paratlon The financial statements are prepared on a 80Sng concern basls, under the hlstorlcal cost ¢onverttlon modified to include the recognltlon of115ted Investments meas¢Jred at falr value, which Is consistent wlth the prior year. The financial statement5 have been prepared in accordance wlth the Statement of Recommended Practlce: Accounting and Reportin8 by Chafities I"The SOAP"), Ihe Financial Reportin8 Standard appllcable In the Unlted Kln8dom and Republlc ol Ireland IFR5 1021 and the Charities Act 2011. The Brltlsh Society for Immunology I"The Society'l meets the definition of a public benefit entlty under FAS 102. General Informatloft The Society is a charitable company Inwrporated in England and Waleg l¢ompany number030059331 and is a charlty reBistered In En8land and Wale5 (charity number 10432551 and re8lStered as a chaflty In Scotland Icharlty number SC0473671. The Soclety's re8i5tered addre55 is Devonshire House 60 Goswell Road, London ECIM 7AD crltlcal accountlng lud8em•nts and k•y Sour￿ ol •stimatlon uncertalnty The preparatlon of financSal statements requlre5 the Sue Of certaln ¢rltlcal accountlng estlmates. It also requlres management to exerclse Sts judgement In the process of applylng the Group and Soclety a£couniing policles. In the applicatlon of the accountin8 policies, Trustees are required to make lud8emenls, estlmates and assumptions about the carrylng value of assets and liabilities that are not readlly apparent from other sources. The estlmates and underlyin8 assumptlon5 are based on hlstorlcal experlence and other factors that are consldered to be relevant. Actual results may differ from these estlmates. The estlmates ènd underlySng assumptlons are revlewed on an ongolng basis. Aevi51ons to accountln8 estlmates are reco8nlsed in the perlod In whlch the estlmate15 rev15ed if the revlslon only affects that perlod, or In the perlod ol revlslon and future perlods if the revision affected current and future perlods. In the vlew of the Trustees, no a5sumptlons concernln8 the future or estlm3tl¢n unceftainty affettlng assets or Ilabllitles at the ba5ènce sheet date are Ilkely to result In a materSal adlustment to thelr ¢arryin8 amounts in the next financlal year. Golngconcern The financial statements are prepared on a Boing conceTn basls which a5sume5 the Sotlety and Group will con14nue 10 meet it5 liabilities as they fall due f¢)r a period ol at least twelve months from the date of the approval of these accounts. The Trustees are monitoring the impact of Covid-19 on the Societv and Group. Thls Includes regular r￿eW of the pandemlc'5 Smpact on our members and our ability to deliver our activities a flexible approach to our annual plan. rolllnB forecasts and In depth revlew of actual financlal results. Thè immunolo8y eommunity Is at thè heart of work on Covid-19 leadlngto the Society belng busleT than ever and attractin8 new fundin8 to 5UPPOrt this work. This together with the holdin8 of sgnifi¢ant levels of cash and investments result in the Trustees considering the Society and the Group to be a 80in8 concern. 32

Notes to the flnancial statements IKome All income is recognised once the Soclety and Group has entltlementto Intome, St is probable that Income will be received and the amount of intome receivable can bè measured reliably. Income of the Society is, where applicable, included net of Value Added Tax IVATI and Is allocated to the pedod to which It relate5, carryin8 forward that part of the Income relatin8 to future accountlng periods. Investment Income Is recoBni5ed on a receivables basis and when the amount can be measured rellably. Expendbtur• Llabllltles are recognlsed as soon a5 there Is a legal or con5tructlve obligation committin8 the Societv and Group to that expenditure, it Is probable that settlement wlll be requlfed and the amount of obli8ation can be measured reliably. Expendlture Is reco8nised on an a¢¢fuals bas15 as a Ilablllty Is Incuired, Intluslve of VAT. whlch cannot be recovered. Expenditure is allocated to a particular activity where the cost relate5 dlre¢tly to that activity. The Cost of overall dlrectlon and admlnistratlon of e•¢h activity, known as'support cost5" and compr151n8 the salary and overhead c05t5 of the central functlon15 apportloned based on staff tlme attrlbutable to Support costs also include governance costs, whlch comprlse organlsatlonal admlnistratlon and compliance wlth constitutional and statutory re9ulrements. The allo¢aiion of support 8nd ¥oveman¢e costs Is analysed in notes 7 and 8. Employ•e b￿￿fits Short-term beneflts includinB hollday pay are recognlsed as an expense in the pwlod In whi¢h the serylce Is recelved. Termlnation payments are accounted for on an accruals basls and line wlth FRS 102. The Soclely contrlbutes to a Group penslon scheme, the assets of whSch are admlnlstered by Royal London Plc. They are deflned contrlbutlon schemes. All contrlbuted costs are accounted for on the basls of char8lng the cost of providln8 penslons over the perlod when the Soclety and Group benefit5 from the employees, servlce. The So¢iety and Grgup has no further Ilabllity under the scheme. Leasln8 and hlr• purchas• commltm•nts Rentals paid under operatin8 leases are charged to the Income and expenditure account on a straight Ilne basls over the lease term. The Sotlety holds no assets under flnance leases or hlre purchase contracts. T•￿￿1b1• fixod assets Tangible assets are stated at ¢05t le55 occurnulated depreclation. Cost Includes the orlglnal purchase price, c05t5 directly attributable to brlnBln8 the asset to its workin8 tpnditlon for it5 intended use, dlsmantlSn8 and restoration costs, The mlnimum ihreshold is £l,CW. Depreciatedls provlded at 33% In order to wrlte off eaeh asset over its estimated useful life. IntanBlbl• flx•d assets Intangible a55ets are stated at cost less accumulated amortlsatlon. Cost Includes the orlginal purchase price, costs dlrectly attrlbutable to brinBlnB the asset to its workin8 condition for it5 intended use, dlsmantllng and restoration cost5. The minimum threshold is £l,(M)). Amortisatlon is provided at 20% in order to write off each asset over its estimated usef*Jl life. Assets in the couw of construction are not amort15ed.

Notes to the flnanclal statements Inwstments Investments are a form of baslc financial instrument and are Inltially shown In the finan¢lal statements at fair value. Movements In the fair value of investments are shown as net gains and losses in the Statement of Financial Artivitie5. Profits and losses on the realisation of Investments are shown as reallsed 8alns and1055es In the Statement of Financial Activitie5. Net glbns and losses on investments are calculated between sales proceeds and their opening carrying value5 or their purchase price if acquired subsequent to the first day of the financSal year. Unreallsed Balns and losses are calculated as the difference between the falr value at the year end and thelr carrylng value. Reallsed and unrealised Investment 8ain5 and ltssse5 are ¢omblned in the Statement of Financial Aetlvltle5. The Snvestment in the subsldlary undertaklng Is Included at cost wlth prov151on beln8 made for anv permanent dlmlnutlon In value. Fbn•nclal Instrum•nts 11 Flnanclal assets 8a51G flnanclal assets, IncludlnB trade and other receivable5, cash and bank balances, are Inltlally reco8nlsed at transaction value and subsequently measured at amortSsed cost. Other financlal assets, Includln8 Investment5, are initlally measured at falr valuÈ. Flnanclal assets are dereco8n15ed when.. al the ¢ontra¢tual rl8hts to the cash flows of the asset expire OT are Settled, or bl substantlally all the rlsks and rewards of the ownership of the asset are transferred to another party or cl despite havin8 retained some sl8nlftcant rlsks and rewards of ownershlp, ¢ontrol of the asset has been transterred to another party who has the practical ablllty to unilaterally sell the asset to an unrelated third party wlthout Imposln8 addltlonal restrlctlons. Cash at bank and cash In hand Includes ￿$h and short-temi hlghly Ilquld Investments wlth a short maturity of three months or les5. 8asic financial liabillties, In¢ludlng trade and other payable5. are Inltlally reco8ni5ed at transaction prlce. Trade payable5 are obll8atlons to pay for goods or servlce5 that have been acqulred in the ordlnary course of buslness from suppllers. Account5 payable are ¢lassifled as current Ilabllltles If payment is due within one year ur le55. If not, they are presented as non-current liablllties. Flnan¢lal Ilabllltles held at amortlsed cost comprise all ¢redltors except social securlty and other taxes and provisions. Prtyrfslons Provlslons are recognlsed where the Society has a present legal or construcrlve obli8ation resultln8 from a past event that will probably result In the transfer of funds to a third party and the amount due to settle the obliBation can be mea5yred or estimated reliabty. Provlsions are measured at the present value or the expendltures expected to be required to settle the obligatlon.

Notes to the flnanclal statements Fund K¢ourtin8 Unrestricted fund5 are those funds available to the Society and Group for8eneral purposes. Thev Include funds desi8nated by the Trustees for partitular purposès where their use remalns at the dlscretlon of the Trustees. It is the policy of the Trustees to retain in unrestricted funds, amounts whl¢h in their jud8ernent, can help to mitigate the short-term effects of Income volatlllty- and retaln as long-term investment funds to 8enerate sufficlent Intome to meet ¢urr•nt and future operational act&￿tres of the 5otiety. Rest￿tted funds are those funds avallable to the Soclety and Group restrlrted to a speclfic purp05e or are subject to particular donor Imposed condltlons. Further informatlon is available in the reserves sectlon of the Trustee5' report. 35

Notes to the Ilnanclal statements In¢om*lrom irants and donatlons 2021 Total funds 2020 Total funds £'ooo Unre5tr1rted funds Re5trlrted funds Grants Donatlons Total 149 39 188 149 41 190 loo loo Incom• from In¥•stments and Interest 2021 Yotal 2020 Total £'oty) IIM•sirlctsd R•rtrlct•d Llsted Investments Investment Income Bank deposlt Interest Total 113 113 109 113 113 112 In¢om• from ¢harllabl• a¢tl¥ltl4s Unrotrlct•d funds Rostrlct•d fund$ 2021 Toi•l fvn¢ts 2020 Total fund5 Member subs¢ripllons Corporates and Partnershlp Income Congress Meetlng5 and events Journals Total 145 78 145 78 170 61 464 45 1.282 2.022 105 1,552 1,552 36

l Noteg to the fi￿n¢la1 statemenls 5 Awa￿0nd erants 1021 Tot•1 ds 20ZO Totsi runds Awbrds and innts to IThJI￿duIls Other Award5 and Grants Support Costslnote 71 Total 104 20 25 32 136 Awardsnd 8rantswere pald to a thtèl of 36(202￿248) Indlvlduals. Unv•strfcted nd5 A•rtrkt•d fundi fund T•t•l Rolsinofvnds Investment Man￿ernent fees Fundr415In Cljorltoble Ex¢ehdltU￿.' Èmbershlp A¥Ybrds •nd irants Coniress Other meetlngs and events PubllcatlonsandlourTro15 Pollcy and Publk Affalr5 VK-CIC Portner5hlpwofk Educarlon and Cweers Publlc en6aBement Communlcatlon5 Internatjonal Work Total 36 13 156 25 166 253 377 176 156 25 166 253 377 181 161 Il8 67 73 169 32 161 31 62 73 146 32 23 Allocatlon of support C05t$to chaThble id1v1t￿S'. Dlrntt 15ts Sypport 2021 Totsi Rolslnqfynas Investment manaBemefft lèes Cost of rnlsln8 funds Choritobleortlvfrles Membershlp Awards and 8rants Congre5$ other meetkn85ande¥ents Pybrtclon5 and journals Pollcy and Publlc Affalrs UKIIC Partnershlpwork Education and Career5 Public en838Lment Communlcations Internath)nal Wo Total 36 91 65 156 25 166 253 377 140 211 313 118 161 iio 47 52 91 32 21 63 161 118 67 73 169 32 1.827 21 78 37

Notes to the flnanclal Statements Total expendlture {£ontlnuedl Support ¢05ts are a5 follows.. 2021 2020 £'ooo stsff costs Premlses costs 185 254 71 91 Depre¢lation and electronlc communlcatlons costs 6S 60 Other 50 105 Recruitment fees Governance costs (note 71 Totsl io 12 li 401 538 Support costs have been allocated based on tlme spent by departments supportln8 the various actI￿t￿e5. Unrestrlrted funds £'ooo Desl8nated lunds Restrlcted lunds 2020 £'ooo £'ooo £'ooo Rolslngfunds Investment mana8ement fees Fundraisln8 Choritable Expendlture.. Member5hlp Awards and grants Con8ress Other meetlngs and events Publlcatlons and Journals Pollcy and public affalrs Educatlon and tareers Publlc en8a8ement Communlcatlons 33 33 12 12 183 183 136 136 587 587 267 267 358 358 173 18 191 75 75 63 23 86 183 30 213 International work 36 36 Total 2,106 71 2.177

Notes to the flnanclal statements Go¥erTran¢e costs 2021 2020 £.￿0 Audltorfs remuneratlon- audlt Auditorfs remuneration- other li io Total 12 li N•t In¢om¢ b•lore yln511055e51 on knw•5tm•nts Thls15 Stated after char8lng'. 2021 2020 £'OLKJ Staff Costs (note 91 Operatln8 lease rental Depre¢latlon Audltorfs remuneratlon audlt Auditorf5 remuneratlon- other 1,103 70 905 90 li io 39

Notes to the financial statements 9 stsff ¢￿ts Stsff costs durin8 the year were as follows.. 2021 'ooo 2020 £'ooo Wa8es and salarles Soclal securlty rosts Pension costs Tot31 962 97 44 781 84 41 905 The avera8e monthly number of employees dufln8 the year was as lollows.. 2021 Z020 Direct charitable activities AdminSstratlon of the charlt 17 14 20 18 Number of employees whose annuallsed èmoltsments fall wlthln followln8 ranges for the year.. 2021 2020 £60,001- £70,000 £70,CQI- £80,OLY) £120,CKJI - £130.000 £130,CK)1- £140,ooJ Pension ¢ontrlbutions for these employèes were £19,62512020- £9,481). The number of staff forwhom retSrement beneflts are accruln8 under money purchase penslon schemes amounted to 21 12020- 161. The Society conslders Its key management personnel comprlse theTrustees and the Senlor ManagementTeam (Smn. The Trustees provlde thelr tlme free of char8e. The total remuneratlon, employer's natlonal Insurance contrlbutlons, benefits and pension5 paid to the SMT wa5 £484,19212020- £436,269). The ￿leVant staff costs have been Included In the costs of charitable act￿ltIeS. Th• gender spllt In the soelety workforce Ss 74% female 26% male12020'. 74% female 26% malel. roles are evaluated and pald In accordance wlth external benchmarklng Irrespertlve of gender. 10 TNswes' remuneratlon No trustee recelved any remuneration for hSs or her servlce5 durln8 the year12020- none). Durln8 the year expenses totsllin8 £nil12020- £7,984) were relmbursed to nll trustees12020- 101. One trustee recefved a prlze of £25 for best presentatlon as voted by attendees of a reelonal meetlng12020- none).

| Notes to the Ilnanclal statements 11 T•nBlble •￿ts att￿ GrnupaThl thavity Computer •qutpTnent rnfurblshmont equlpment andfurnlture lrnpthement Total C( or V41￿15￿n At l July 2020 Addltlons 72 22 loo li li Disp05als At 30 lune 2021 1541 29 161 1221 1821 29 Depr•datloTh At l July 2020 Charge forthe year Ellmlnated on dlsposal At 30 June 2021 59 22 87 1571 li 161 1851 li N•t book v•lu• At 30 June 2021 IB 18 At l July 2020 13 13 Iffl•wlbl• ofihe Group4nd ¢h•rlty Total Cos¢ or v•lwtSon Atllu￿2020 Addltlons 37 37 Dlsposals At 30June 2021 37 37 DeprcIat￿N At l July 2020 Charge lorthe year Ellminated on dlsp¢)sDI At 30June 2021 Net book val At 30 June 2021 37 37 At l July 2020 Construction ol a new CRM system started In theyear and 15 expected to be completed nexiyear. 41

Notes to the finan¢lal statements 13 Investments Group 2Q21 Chartty 2021 2020 2020 £'o £'o £'ooo Mab*•t value •t l July 2020 D15posals proceeds Reallsed losses 3,693 15991 3.632 16731 1211 622 3.693 15991 46 3.632 16731 1211 622 AddltKJns at cost 595 595 Unrealised 8ains Mark•t valuo at 30Jun• 2021 461 131 461 131 4.196 258 3.692 178 4,197 258 3,693 178 Cash held wlth Investment mana8ers Total Investments 4,454 3,871 4.454 3,B71 Total Group Investments Includes £1￿ Investment In subsldlary Group Chlrlty At 30 lune 2021 the 115ted Investments mprlsed the followln8'. 2021 2020 2021 2020 £'oty) £'ooo UK equltles Overseas equltles Investment Instruments 1,157 1,510 1.643 718 1.157 I,sio 1,643 718 1.353 4.454 1,353 4N54 Tth•l 3.871 3,871 Hlstorlcal cost of Ilsted Investments 3,470 3,268 3,470 3,268 At 30 lune 2021 the holdln8 In ASC IOf15horel Sterllng Flxed Interest Fund Z Inc. represents 5.06% of the total market value of the portfollo of Ilsted Investments.

Notss to the financial statements 13 lTh¥estments Icontlnue411 In¥estment1ftsubs￿wndethAnO The Socletyowns ILM)% of the ordlnary Issued thare capltal of 8SI Tradlng Llmlted. a cornp•ny registered in E￿land and Woles (Company numbEr010217391. its reK15tered addre5515 Devonshlre House. 60 Goswell Road. London ECIM 7AD. The prtnclpal ac￿¥￿ty0f the company15the mona8ement of corporate member5hlp. sponwrshlp, exhlbluon and other tradlng •¢t1￿tle$for1hI Soclety. A summary ofthe iesuttsof ihe subsldlary is 5hov4ft below.. 2021 2020 É'oc Tumover 133 307 Costs Operatlng proflt 133 307 Adminlstratlon cwts iioi ProAtllossl for the flnanclal period 123 293 DlstrlbthlDn to p•reTht c￿rtty Rel•ln￿ In sUb￿d1￿Y The company's assets and Il&bllltles at 30June 2021 were as lollow$'. sets 233 Llabllltles 11471 233 14 Debtors Gr￿P 20Zi Chwlty 2021 2020 2020 £'wo Tradedebtors 14 15 14 Other debtor5 Prepayments•nd a¢¢rued Income Amount owed by5ub51diory undertakln8 VAT re￿1¥able 92 106 92 106 134 310 24 24 Tota lao 122 164 418

Notes to the financial statements IS Creditors Group 2021 Charlty 2021 2020 2020 £'o £'ooo Trade credltor5 40 33 Other taxes and soclal securlty costs VAT payable other credltors Accruals and deferred Income 49 39 49 39 40 40 13 18 13 18 829 786 790 Tol•l 922 965 920 Included wlthln the above Is deferred Income as set out below: Group Ch•Aty 2021 2021 Deferred Income brou8ht forward at l Julv Addltlonal Income deferred durlng the year Brought forward funds released In the year Delerred in£om& £arri¢d lonvard a130 Junq 919 919 800 800 19191 8fy) 19191 786 Deferred Income comprb5e5 advance payments of journal royaltle5 and membershlps fees. 16 Operatln8 leases The total future mlnlmum lease payments under non cancellable operailn8 lea5e515 as follows: Land and Bulklln8s 2021 2020 Payment5 which fall due.. Wlthln one year Between one and two years 47

Notes to the flnanclal statements 17 Restrtded fvnds At l July 2020 At 30 Jun• 2021 Income Eyndlture Meetlni funds Celebratevaceines 34 io iioi Covfjd.19 13 Conrte¢ton t¢ro￿vIrUS Autolmmunlty UKIIC 15 io 137 11611 1261 1241 Vacclne ts5kforce 26 Iteslied Immunologv Total 57 191 12Z31 25 Meetlng funds Oonations to the Society by Indlviduals to promote certain Immunolo8lcal Issues. Celebrate Vaccines The New Venture Fund 8rant provlded to enhance the success of the Gavl 2020 replenlshmenL though the BSI'S Celebrate Vacclnes campalgn. Covld-19 A erant from ihe Lorna Ind Yuti Chem•lo¥sky Blomedlcal Research Foundatlon for 851's work ort Covld-19. Conn•rt on Coronavlrus Atlonètlen to fund the 5oclety's serles of weblnlrs prowldlng Informatlon whlth may rontrlbute to the understsndlnz and treatment of COVID-19. Autolmmunlty A grant from the Ltsma ènd Yutl Chetn•jovsky Biomedical Resehrch Foundatlon for admln15tratlve 5LlPPOrt for the developmeni aThd manaiementof the autolmmune research Inlllatlve. UK.CIC Agrantfor the 051 support provlded to the UK Coronavlrus Immun01￿V Consortlurn IUK-CICI. Involce5 are ra15ed quarterty fcr expenses Incurred, theflnal Involce for relmbursement of the remaln5n8 costs ￿1( be raised afterthe ye8rend. Vacclne tasklorce A 8rant from the European Federatlon of Immunolo8Scal Socle¥es IEFISI forthe EFIS VacclneTa5kforce wgrk1ed bv the B51. Biteslzed Immuno108y Donations recelved to update the BS1'5 onllne resource. BlteSlzeL* Immunolo8y. whlch pro¥Trde$8 comprehensl¥e wlde tothe Immune system especlally sUitsb￿for blomedlcal under8raduatesand those new to Immunologv. 45

Notes to the financial statements 17 Restrlrted funds (Cmtlnuedl At l July 2019 £'o At 30 June 2020 £.￿)0 Income E¥pendTrture £'oth) Meetlng lunds Celebrate vacclnes Covid-19 34 74 20 1641 io 13 Total 94 711 57 18 D•sl8nated funds At l Julv 2020 0•518nated In y•ar Utlllsed I releas•d At 30Jun• 2021 Long temi sustainablllty Offke refurblshment CRM project Career development progr8mme 150 IQD 100 248 iiooi 150 625 113 625 250 11391 Lon8 temi sustalnablllty The loni terrn 5U5ts1nabllitylund prO￿deS resources for Investln8 In the finar￿al 5UStaln•blllty of the thadty ovef the next Ilve ye4rs. Offlc• r•lurbIshm￿t Fundsdesl8nated for office refurblshment were rde•sed when the office lease w4$ not renewed CRM project Thecftm wole¢tfund yovldes resources to develop aThd Implement B new CRM system toiether wlth an U￿rade to thé 8SI webslte Career development programme The Career develcpment prD8ramme wlll lund o sl8nfficant empanlon In the careers svpport the 851 offersio our members. Th1$ IrKludestwo maln 5treams.' our£areer*nablln¥ actlvltles and ouv caretr.enhan£ln8 actlvlties. 46

Notes to the flnancial statements 19 Analysls of nets assets between fundj 2021 Unrestrlrted funds Deslgnated fund5 £'ooo Restrlcted funds Total funds Group Tangible fixed assets Intangible assets Investments Current assets Curfent liabilities Total Funds 18 37 4.454 346 19221 3,933 18 37 4,454 1.357 19221 4.944 986 25 2021 Unrestrlrted fi4nds Deslgnated fullds £'cKJo Restrfct¢d funds Totsl lynds Chartty Tan8lble flxed assets Intanglble assets Investments Current assets 18 37 4.454 332 19081 18 37 4,454 1,343 1908 986 25 Toial Funds 25 The total unreallsed galns Ilossesl as at 30June 2021 constltute5 movements on revaluatbon and a￿ as follows.. 2021 2020 £'ooo Unrgallsed g¥ln51I055￿) Includ•d above: On Investments Total unTea115ed Balns (losses) at 30June 983 983 391 391 R•condllatlon ol mov•m•nts In unrwlls•d galng Iloss•sl Unrealised gains ai i July Less.. in respect to dlsp05als In the year 522 391 522 391 Add.. net galns Ilossesl arlsln8 on revaluatlon arlslng In the year 461 13L Totsl unreallsed bns losses at 30 June 522 47

Notes to the financial statements 19 Anatysls of nets assets b•tw•en Icontlnuedl 2020 £￿0 Group Tangible lixed assets Investments Current assets 13 3,871 852 19651 3.771 13 3,871 1,159 196SI 4,078 250 57 Total Funds 250 57 2020 Unrestrl¢ted fvnds 0•518nat•d funds £'ooo Restrlct•d funds £'(#Jo Total funds Charlty £'o(M) Tangible fixed assets Current assets 13 3,871 807 19201 3.771 13 4,178 807 19201 4,078 250 S7 Total Funds 250 57 20 Sh•r• upltal The company Is Ilmlted by 8uarantee and therefore has no share capttal. Each member's Ilab411ty Is Ilmlted to £1. 21 R•lat•d party transactlons An oral prlze of£25 was made to Emma Chambers at a London Immunology Group meetlng. Calum Baln Is a member of the EdltorSal Board of Immunology, no payments were made In relatlon to thls. There were no other related party transactlons that reqtblred dlsclosure In the current flnanclal perlod12020.' none).

Notes to the financial Statements 22 C¢xnparatl¥e ¢onsolldated ststernent of IlTrandal actlvld UTrrestricred funds De518nated Rèstritted 2020 £oc) l¥rtom•from: Donatlon$ Inb5tfflents Ic IL2 Charttable &LMt￿¥ Membershlp Partner5hlpwork C¢n8ress Mtetlngs ondevents 170 170 61 61 464 464 45 1.282 1.140 1.282 1.254 Tot•1 In￿mI 94 RoYlsJnglunds lnvestmenl Mana8ernEfflt Fee5 Cost of ralsln6 fund5 thodtobltccuvlt ernbershlp A¥￿r45 and yints Cowress Meetln6s•ndevents Puwltstbnsènd lournJls Pollcy and PubllcAffaif5 Edutat1oN Cireerj Publk eniagernenl Communlcatlons Intemitlonal ¥work Tthal upffidltw• 33 12 12 183 136 587 267 183 136 587 267 358 19) 77 J73 18 75 Ga 23 183 213 36 36 2,IOG 2.179 14•t kK•m• bthilns on hv•wtm•r NetgaIn￿IlO1$esI on Inve5tment5 Tfansforsbotsveen funds Nèt kntom• 34 23 ss 11441 144 142 23 165 R•¢onal•rknoffvnds.' Fund5 brou8htfoMrd 3.771 L( 3,911 Fund5 c8rrledfuNwartJ 3.771 248 57 4.076 49

Notes to the financlal ststements Charlty 5tstemeni of fin•ncl•l acll¥hles Unre5trirted lunds General funds Desl8nated funds £'o Restricted funds £'ooo Total 2021 £'ooo Total 2020 Income from: Grants and donatlons Investments Charitablé artivities Membershlp Partnership work Con8ress Meetln8s and events Journals Glft Ald and recharge from BSI Tradln Limlted Totsl Incom• 188 190 113 Icx) 112 113 145 io 145 io 170 208 57 1,282 41 1,552 1,552 132 132 305 1,995 191 2,186 2,234 Exp•ndlture on.. Ralslni funds Investment management fees Cost of rai5inB funds harliabl• •ctlvltl•s Membershlp Awards and grants Congress Meetln8s and event$ Publlcatlons and lournals Pollcy and Publlc Alfalrs UK-CIC Partnershlp work Education and Careers Publlc engagement CommunScatlons International work Total •xp•ndllure 36 13 36 13 33 12 156 25 166 253 377 176 156 25 166 253 377 181 161 118 67 73 169 32 1,827 183 136 587 267 358 190 161 31 87 62 73 146 32 1,602 75 86 213 36 2.177 23 223 Net Incom• lexpendlturel b•fore galns {loswsl on Inwstments and transfers Net 8ains/llossesl on investments Tran51ers between fvnds Nèt Incornelldelklrl 393 1321 359 57 507 507 iio 738 162 738 736 1321 167 Recon¢lllatlon of funds: Funds brought forward 3,771 250 57 4,078 3,911 Funds carried forward 25 4,078

Board of Trustees 202(￿21 Board attendance 202Lk21 Commlttee attendance Posltlon Current office holder appointment I re51 natlon 201>20 committoes Forum, Nominations & Con8re55 Commlttee5 Flnance S¢Jb Committee & Con8rÈ%s Commlttee Foium & Nominatlons Commlttee Appointed December 2018 414 iii 214 President Professor Arne Akbar 515 Treasurer Dr Flona Culley Appolnted Juty 2017 515 515 414 Chalr of Forum Professor Ann Ager Appolnted December 2018 51S 414 tyi Forum, Cllnlcal & Congres5 Committees Cllnlcal Secretary PTofe5sor Colin Dayan Appolnted October 2019 314 214 $15 Ear￿ Career Trustee Earw Career Trustee Dr Calum Baln Appointed July 2018 Appolnted De￿rnber 2018 Appointed October 2016 Appolnted July 2019 Appointed Janua 2017 Re-appolnled Jul 2019 Appointed Janua 2017 Appointed lulv 2019 Re-appolnted Ma 2019 Appolnted December 2018 515 Dr Emma Chambers 515 CL>QPted Trustee Robert Davles 515 Nomlnations Commlttee ill Trustee Professor Deborah Dunn.Walter$ Professor Matthla5 Eberl 315 Trustee 515 Nominations Commlttee Flnance Sub CoMM￿ee Iii Co-QPted Trustee Dr Paul Hardln8 515 sis Co-opted TfUStee Dr Edith Hessel 515 Co-opted Trustee Jame5 Lowe 415 Flrtance Sub Committee 515 Trustee Professor Allan Mowat 515 Trustee Dr Dlvya Shah Nomlnatlon5 Commlttee 515 iii 51

rnana8ement ￿lsOn￿OI Name Posltlon Dr Doug Brown Chlef ExecutSve Otto Ba15i8er Finance Oirector Orjennle Evans Dlre¢tor of Extemal Affal Jane Sessenwein Head of Events & Conferences Lury M¢lver Head of Publishing Prlndwl wofe5Jlonil •d¥lser5 Posltlo Bank of Scotland 14116 Cockspur Street London Bankers EC2V 6DL Moore Klngstort Smlth LLP Devonshire House 60 Goswell Aoad External audltors London ECIM 7AD Aberdeen Standard Capltsl 14th Floor Investment ad¥Asers 30 St Mary Axe London EC3A 88F Russell Cooke LLP Solldtors 2 Putney Hlll London SW15 6AB 52

Committees Nomlnaiions Committet Name Posltlon Profes50rArne Akbar PTofes50rAnn Ager Robert Davies Chair, BSI Presldent Forum Chair and Trustee BSI Co-opted Trustee Trustee Profes50T Matthlas Eberl Dr Divya Shah Dr Dou8 Brown Trustee BSI CEO lobserverl Flnanc• Sub Comrnlttèe Namé Posltlon Dr Flona Cullev James Lowe 851 Treasurer Ctsopted Trustee Ctropted Trustee 851 Chlel exeeutlve Paul Hardln8 Dr Doug Brown Forum Name Posltlon Professor Ann ABer Professor Arne Akbar Chalr 851 Preseldent Clinical secretary Educatlon & Careers Secretary Publlc EngagèmÈnt Secretary 851 Chief Executive Dr Colin Dayan Dr Oonald Palmer Professor Donald Davldson Dr Dou8 Brown Dr Me8an Macleod Dr Helen McGettrkk Regional Representatlve- 5wtland RegSonal Represeniative- England Reglonal Representatlve- Northem Ireland Regional Representstive- Wales Early Career Representatlve Early Career Repiesentative Early Career Representative Early Career Represenlative PhD Representatlve PhD Representatlve Industry Representative Cllnical Representative Clinical Representative Veterinary Representative Dr Karlm Dlb Dr Sirnone Cuff Dr Louise Toppln8 Dr Alice Burton Dr Faith Uwadiae Dr Edoardo Predilètto Dr Lauren Campbell Dr Nlamh Richmond Or FÈderita Villanova Dr Matthew 8uckland DrTomaz Gar￿1 Dr Elma Tchlllan 53

mmlttees Congrèss Commlttee Name Posltlon Professor Gary Entrlcan Professor Arne Akbar BSI Congress Secretary BSI President Dr Fiona Culley Dr Colln Dayan Professor Mark Coles BSI Treasurer BSI Clinlcal Secretary BSI Con8re55 Secretary Elect Member Professor Linda Wooldrldge Professor James Brewer Member Dr Martina Colicchla Early Career Representstlve FP I Dr Alexandra Spencer Dr Deena Gibbons Member Member Drjohn Tre8onln8 Dr Slnlsa Savlc Member Cllnl¢al member Member Dr Mar8arlta Domin8uei Dr James Harker Member Dr Graham Cook Member Dr Sandfa Sacre Member Cllnlcal CommStte• Mame P051tion Dr Adrlan Heap5 Dr Rlthard Herrlot As50clatlon for Cllnlcal Blochemlstry A550clatlon of Cllnlcal Patholo8lsts Institute of Biomedlcal Science Dr Chris kott Dr Tarlq El-5hanawany Dr Stephen HuBhe5 Dr Slraj Mi5bah Dorothea Grosse-Kreul rltlsh Soclety forAller8y & Cllnlcal Immunologv Brlt15h Paedlatrlc Allergy Immunolo8y & Infectlons Group Speclal Adwsory Commlttee on Immunolo8y IRCPath SAQ Immunology & Allergy Nurses 8roup Trainee Rep Joint Committee on Immunology & Allergy IJCIAI UK Primary Immunodeficiency Network IUKPINI Chairlciinical Secretary BSI Chlef Executive Dr Kavltha Sooriyakumar Dr 5hualb Nasser Dr Sinisa Savic Dr Colln Dayan Dr Dou8 Brown 54

| Journals Immunology - Edltorlal Tearn Name Professor Simon Millin Dr Awen Gallimore Dr Florent Glnhoux Piofes5Qf Kathleen Mccoy Professor Francisco J. Quintana Position Editor-irt-chief Associate Editor Assoclate Edltor Associate Editor Assoclate Edltor Dr Meera Ramanujam A550clate Editor Cmftklolond Expethfttol Imffiunolopy . Edltorbal Tèam Name Posltlon Professor Leonle Taams Edltor-In.Chlef Professor Angelo Manfredl Professor Tanja de Gruiji Professor Clrlaco Plcclrlllo 5ecllon Edltor- autolmmunlty Section Editor- cancer immunltv Sectlon Edltor- Immune-medlated Inftammatory dlsease5 Section Edltor- Immunodeflclency Section Editor- Infectlous diseases and vaccines Dr Clndy M Dr daniel Douek Professor Xlao-Nlng Xu Professor Sandra Amor Sectlon Edltor- Infectlous dlseases and vacclnes Sectlon Edltor- neurolmmuno108y ImmunotherqpyAdwnces - Edliorlal Te•m Name Posltlon Professor TIM Elllot Edltor-In.Chlef Professor Stefan Barth Assoclate Professor Marlanne Boes Professor Adrianna Bonomo Re8lonal Editor.. Afr1¢ Aeglonal Edltor.. Europe Regional Edttor.. South America Re8lonal Edltor.. A51a Regional Edttor.. North Amerlca Professor Tao Dong Dr Stephanle K Dougan Assoclate Professor Menno van Zelm Reglonal Edltor.. Austr01asla 55

e8ional and Affinity groups Affinlty Grou Group Position Chair Professor Lucy Walker Autoimmunlty Affinity Group Secretary Dr Kathryn Steel Treasurer Dr james Pearson Re518ned 2019 Secretary Dr Elma Tchilian Comparatlve Veterlnarv Immunolo8y Group Dr Lindert Benedi¢tus Treasurer Dr Kate Sulton H15to¢ompatiblllty & Immuno8enetlC5 Group Chalf Professor David Bri88S Secretary Dr Luke Foster Co-chalr Dr Laura Pallett Immunometabollsm Afflnlty Group Co-chalf Dr ts.nda Sinclalr Secretary Dr Sarah Dimeltse Tfeasurer Dr Anna Schurlch Chalf Dr Slan Henson Immuno$enescence Afflnlty Group Secretary Treasuier Dr Natalle Riddell Dr Catarina Henrlques Infectlon and Imfflunlty Group Chalr Professor Peter Barlow Inllammatlon Afflnlty Group Treasurer Drjoanne Konkel Communlcatlons Dr lack RiversAuty Chjlr Dr Myrlam Chlmen Leukocyte Migratlon Group Secretafynreasurer Dr Graeme O'Boyle Professor Carmen-molina Paris Ch3lr Mathematkal Modelllng Group Secietary Professor Mark Coles Treasurer Professor Grant lythe Chalr Professor Sandra Amor Neurolmmunolobry Group Secretary Dr Sarosh Iranl Chalr Dr Phll Ho8arth Drjulla Tree Vaccine Affinity Group Secretary Treasurer Dr Bernardo Vlllarreal-Ramos Chalr PTofessor Benjamin Wlllcox Dr Seth B. Coffelt Tumour Immuno108y Affinlty Group Secretary Treasurer Professor Awen Gallimore 56

Re8lonal and Afflnlty groups Re8lonal Group5 Group Posltlon Chair Dr Isabel Crane Aberdeen Immunolo8y Group Treasurer Dr 5oumya Palllyll Chair Dr Laura Rivino Bristol Immunology Group Secretary Dr Dronwen Burton Treasurer Dr Undsay Nlcho150n Cambrld8e Immunolo8V Group Chalr Dr Brian Ferguson Secretarynreasurer Dr Louise Boyle East Anglla Immunology Group Secretary Dr Marla O'connell Treasurer Dr Crlstina Fanuttl Co-chalr De Ceclle Benezech Co-chalr Dr Laura Mccullock Edlnburgh Immuno108y Group Secretary Dr Matthew 8ur8ess Secretary DrTovah Shaw Treasurer Dr Davld Donald50n Chalr Professor Rlchard Grencls Greater Manche51er Immunolts￿ Group secretary Dr Ana Vllle8as-Mendez Treasurer Dr joanne Konkel Chalr Dr Kevln Marchbank Immunology North East Secretary Dr Antony Antoniou Treasurer Dr Andy Knlght Chalr Dr james Harker London Immunolo8y Group Secretary Dr Laura Pallett Treasurer DrAllce Burton Merseyslde Immunolo8V Group Secretsry Dr Qibo Zhang Treasurer Dr Steve Chrlstmas Chalr Dr Alexandia Spencer ctssÈC￿1ary Dr Loulse Johnson Oxford Immunology Group CTrSecretary Dr Anita Miliac Treasurer Dr Phlllpp Kruger 57

Re8lonal and Affinity groups lI￿lOnal Groups Group P055tlon Chalr Dr You Zhou South Wale5 Immunology Group Secretèry Treasurer Dr Rebecca Aicheler Dr Cefi Fielding Professor Srrnon Arthur Chair Tayslde Immunology Group Secretary Dr Mahlma 5wèmv Treasurer Dr Stephen Matthew5 President Dryvonne Dombrowskl Ulster Immunoloay Group Secretary Dr Karim Dlb Chair Dr Emma Reeves Wessex Immunology Group Secretary Or Alison Hill Trea5ureT Dr Dio80 Silva Co-chalr Dr Davld Bendlng West Midlands Immunologv Group Co-chair Dr Kendle Maslowskl Secretary Dr Lla Uaskou Treasurer Dr Zhl Ll Chalr Dr Megan Ma¢Leod West of Scotland Immunology Group Seuetary Dr Ed Roberts Treasurer Dr Hannah Scales Chair Dr Glna Doody York5hlre Immunology Group Secretary Dr Er*ca Wilson 58